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ABSTRACT 
5-HT2A receptor (R) antagonists and 5-HT2CR agonists attenuate reinstatement of 
cocaine-seeking behavior (i.e., incentive motivation). 5-HT2Rs are distributed throughout 
the brain, primarily in regions involved in reward circuitry, including the prefrontal 
cortex (PFC), caudate putamen (CPu), and basolateral (BlA) and central (CeA) amygdala. 
Using animal models, we tested our hypotheses that 5-HT2ARs in the medial (m) PFC 
mediate the incentive motivational effects of cocaine and cocaine-paired cues; 5-HT2ARs 
and 5-HT2CRs interact to attenuate cocaine hyperlocomotion and functional neuronal 
activation (i.e, Fos protein); and 5-HT2CRs in the BlA mediate the incentive motivational 
effects of cocaine-paired cues and anxiety-like behavior, while 5-HT2CRs in the CeA 
mediate the incentive motivational effects of cocaine. In chapter 2, we infused M100907, 
a selective 5-HT2AR antagonist, directly into the mPFC and examined its effects on 
reinstatement of cocaine-seeking behavior. We found that M100907 in the mPFC dose-
dependently attenuated cue-primed reinstatement, without affecting cocaine-primed 
reinstatement, cue-primed reinstatement of sucrose-seeking behavior, or locomotor 
activity. In chapter 3, we used subthreshold doses of M100907 and MK212, a 5-HT2CR 
agonist, to investigate whether these compounds interact to attenuate cocaine 
hyperlocomotion and Fos protein expression. Only the drug combination attenuated 
cocaine hyperlocomotion and cocaine-induced Fos expression in the CPu, but had no 
effect on spontaneous locomotion. Finally, in chapter 4 we investigated the effects of a 5-
HT2CR agonist in the BlA and CeA on cocaine-seeking behavior and anxiety-like 
behavior. We found that CP809101, a selective 5-HT2CR agonist, infused into the BlA 
increased anxiety-like behavior on the elevated plus maze (EPM), but failed to alter 
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cocaine-seeking behavior. CP809101 infused into the CeA attenuated cocaine-primed 
reinstatement and this effect was blocked by co-administration of a 5-HT2CR antagonist. 
Together, these results suggest that 5-HT2ARs in the mPFC are involved in cue-primed 
reinstatement, 5-HT2A and 5-HT2CRs may interact in the nigrostriatal pathway to 
attenuate cocaine hyperlocomotion and Fos expression, and 5-HT2CRs are involved in 
anxiety-like behavior in the BlA and cocaine-primed reinstatement in the CeA. Our 
findings add to the literature on the localization of 5-HT2AR antagonist and 5-HT2CR 
agonist effects, and suggest a potential treatment mechanism via concurrent 5-HT2AR 
antagonism and 5-HT2CR agonism.  
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Chapter 1 
General Overview 
Drug addiction is a serious social and financial problem, with an estimated 37% of 
the population having used illicit drugs and over $25 billion spent in 2012 to combat this 
disorder (Office of National Drug Control Policy, 2013). In a recent analysis, 2.4 million 
Americans self-reported current cocaine abuse (SAMHSA). Despite the prevalence of 
cocaine addiction and decades of research, treatment remains inadequate. Psychotherapy 
utilized for some cocaine addicts is often insufficient for long-term abstinence (Alterman 
et al., 1996; K. M. Carroll et al., 2004; Kampman et al., 2001) and there are no approved 
pharmacological treatments available. 
Typically cocaine abuse involves binges during which cocaine is repeatedly taken for 
its psychoactive effects, followed by a period of voluntary abstinence during which 
craving is usually absent initially but then gradually emerges and is thought to motivate 
another binge. Even after prolonged periods of abstinence, cocaine craving can be 
triggered by stress, exposure to cocaine-related cues, or sampling cocaine (Childress, 
McLellan, Ehrman, & O'Brien, 1988; Jaffe, Cascella, Kumor, & Sherer, 1989; Sinha, 
Catapano, & O'Malley, 1999). Though the definition is controversial, craving is thought 
to reflect incentive motivation for cocaine (Stewart, 1983), which in turn, is a major 
factor contributing to relapse.  
The extinction/reinstatement model is used to measure incentive motivation for 
cocaine in animals trained to lever press for cocaine reinforcement (de Wit & Stewart, 
1981). These animals undergo extinction sessions during which cocaine is withheld and 
operant responding under this condition is referred to as cocaine-seeking behavior. 
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Initially, animals exhibit robust cocaine-seeking behavior, which declines as extinction 
progresses. Once the behavior is extinguished, it can be reinstated by cocaine priming or 
presenting cues previously associated with cocaine. The reinstatement is thought to be a 
measure of the incentive motivation for cocaine elicited by these stimuli, similar to cue- 
or drug-primed craving in humans (de Wit & Stewart, 1981; Markou et al., 1993; 
Neisewander & Acosta, 2007). 
Cocaine and Serotonin 
In the brain, a primary action of cocaine is blockade of 5-HT transporters, resulting in 
enhanced synaptic levels of 5-HT (Koe, 1976; Koob, Sanna, & Bloom, 1998; Woolverton 
& Johnson, 1992). 5-HT plays a complex role in cocaine reinforcement and incentive 
motivation for cocaine. In rats, increasing 5-HT neurotransmission via indirect agonists 
fluoxetine and d-fenfluramine attenuates cue-primed reinstatement, cocaine self-
administration, progressive ratio breakpoint, and reward threshold (Baker, Tran-Nguyen, 
Fuchs, & Neisewander, 2001; Burmeister, Lungren, Kirschner, & Neisewander, 2004; M. 
E. Carroll, Lac, Asencio, & Kragh, 1990; Lee & Kornetsky, 1998; Peltier & Schenk, 
1993; Richardson & Roberts, 1991), and chronic fluoxetine administration decreases 
sensitivity to the rewarding effects of cocaine (Baker, et al., 2001; Lee & Kornetsky, 
1998) and decreases cocaine-seeking behavior during extinction (Baker, et al., 2001). 
Interestingly, 5-HT depletion with a tryptophan hydroxylase inhibitor para-
chlorophenylalanine (p-CPA) or the 5-HT-selective neurotoxin 5,7-dihydroxytryptamine 
(5,7-DHT) also attenuates cocaine-seeking behavior (Tran-Nguyen, Baker, Grote, 
Solano, & Neisewander, 1999; Tran-Nguyen, et al., 2001). Similarly in humans, 
increasing 5-HT with fluoxetine (Batki, Manfredi, Jacob, & Jones, 1993; Walsh, Preston, 
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Sullivan, Fromme, & Bigelow, 1994) or decreasing 5-HT via tryptophan depletion 
(Aronson et al., 1995; Batki, Washburn, Delucchi, & Jones, 1996; Satel, Krystal, 
Delgado, Kosten, & Charney, 1995) decreases self-reports of cocaine craving and “high” 
and craving. Collectively, these findings suggest that either low or high levels of 5-HT 
can inhibit cocaine-related behaviors.  
Serotonin Receptor Subtypes 
5-HT is involved in many aspects of behavior and is implicated in many mental 
health disorders including depression, anxiety, and addiction. The wide-ranging role of 5-
HT is likely due to a complex receptor system. Since the discovery of different 5-HT 
receptors in the brain (Peroutka & Snyder, 1979), over 20 receptor subtypes organized 
into 7 families have been identified (Hoyer et al., 1994; Pytliak, Vargova, Mechirova, & 
Felsoci, 2011), all of which are G-protein coupled metabotropic receptors aside from the 
5-HT3R which is a ligand-gated ion channel (Barnes & Sharp, 1999).   
A brief review of the 5-HTR subtypes reveals that the 5-HT1AR is most implicated in 
anxiety (Klemenhagen, Gordon, David, Hen, & Gross, 2006), with a 5-HT1AR agonist 
buspirone a notable treatment for generalized anxiety disorder, as well as aggression (de 
Boer & Koolhaas, 2005; Rickels, 1983). The 5-HT1BR is also involved in aggression 
(Groenink, van Bogaert, van der Gugten, Oosting, & Olivier, 2003) and anxiety 
(Benjamin, Lal, & Meyerson, 1990), in addition to addiction (Groenink, et al., 2003; 
Pentkowski, Acosta, Browning, Hamilton, & Neisewander, 2009) and migraine (Buzzi & 
Moskowitz, 1991). 5-HT1D, 5-HT1E, and 5-HT1FRs are less studied but thought to be 
involved in anxiety, memory, and vasoconstriction, respectively (Pytliak, et al., 2011). In 
the 5-HT2R family, the 5-HT2AR is involved in hallucinations (Glennon, 1990) and 
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addiction (Fletcher, Grottick, & Higgins, 2002; Nic Dhonnchadha, Fox, Stutz, Rice, & 
Cunningham, 2009; Pockros, Pentkowski, Swinford, & Neisewander, 2010), with 5-
HT2AR agonists including hallucinogenic drugs lysergic acid diethylamide (LSD) and 
mescaline. 5-HT2BR ligands have more of an effect peripherally than in the brain 
(Borman et al., 2002; Ellis et al., 1995), however some findings suggest that 5-HT2BRs 
are involved in anxiety (Kennett et al., 1998). 5-HT2CRs are highly involved in appetite 
(Sargent, Sharpley, Williams, Goodall, & Cowen, 1997) and addiction (Neisewander & 
Acosta, 2007; Pentkowski et al., 2010), with a 5-HT2CR agonist loraserin recently FDA-
approved for the treatment of obesity (Halford, Harrold, Boyland, Lawton, & Blundell, 
2007). The 5-HT3R is the only ligand-gated ion channel receptor of the 7 families, and is 
most involved in nausea and vomiting (Gyermek, 1995), with 5-HT3R antagonists used to 
treat the side effects of chemotherapy, as well as a few studies suggesting a connection to 
anxiety and addiction (Rodd et al., 2007; Thompson & Lummis, 2007). 5-HT4Rs are 
mostly studied for their peripheral effects on the gastrointestinal tract (De Ponti & Crema, 
2002), though one study suggests a role in memory and addiction (Reynolds et al., 1995). 
While 5-HT5Rs have not been studied extensively, they may be involved in locomotion 
and sleep (Pytliak, et al., 2011; Thomas, 2006). 5-HT6Rs have been implicated in 
memory, cognition, and mood (Johnson, Ahmed, & Miller, 2008; Woolley, Marsden, & 
Fone, 2004). Finally, 5-HT7Rs appear to be involved in depression and sleep (Hedlund & 
Sutcliffe, 2004; Mnie-Filali, Lambas-Senas, Zimmer, & Haddjeri, 2007). 
While several 5-HTR subtypes have been implicated in addiction, this dissertation 
will focus on the 5-HT2A and 5-HT2CRs. Both receptors are known to play a role in 
cocaine-seeking behavior, with a consistent pattern suggesting that manipulations of 
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these receptors have opposite effects (Fletcher, et al., 2002; Neisewander & Acosta, 
2007; Nic Dhonnchadha, et al., 2009). The 5-HT2AR plays an excitatory role in cocaine-
related behaviors while the 5-HT2CR plays an inhibitory role.  
Peripheral injections of the 5-HT2AR selective antagonist M100907 decrease cocaine 
hyperlocomotion as well as cue- and cocaine-primed reinstatement of cocaine-seeking 
behavior, but have no effect on cocaine self-administration (Fletcher, et al., 2002; Nic 
Dhonnchadha, et al., 2009). Systemic administration of M100907 also attenuates cocaine 
discriminative stimulus effects (McMahon, Filip, & Cunningham, 2001) and stimulant-
induced hyperlocomotion (Fletcher, et al., 2002; McMahon, et al., 2001). Furthermore, 
blocking 5-HT2ARs attenuates MDMA-induced DA release (Schmidt, Fadayel, Sullivan, 
& Taylor, 1992; Schmidt, Sullivan, & Fadayel, 1994) and decreases c-Fos expression in 
the nucleus accumbens (NAc) shell and caudate-putamen (CPu) (Szucs, Frankel, 
McMahon, & Cunningham, 2005).  
Conversely, the 5-HT2CR plays an inhibitory role in cocaine-related behaviors. For 
instance, a selective 5-HT2CR antagonist enhances cocaine self-administration, as well as 
cocaine-primed reinstatement of cocaine-seeking behavior and cocaine-induced 
locomotor activity (Fletcher, et al., 2002; McMahon, et al., 2001). 5-HT2CR agonists also 
inhibit cue- and cocaine-primed reinstatement of cocaine-seeking behavior, effects that 
are blocked by pre-administration of 5-HT2CR antagonists, indicating that they are 5-
HT2CR-mediated (Fletcher, Rizos, Sinyard, Tampakeras, & Higgins, 2008; Neisewander 
& Acosta, 2007; Pentkowski, et al., 2010). Further, 5-HT2CR agonists attenuate 
morphine-induced DA release in the NAc (Willins & Meltzer, 1998), and antagonists 
enhance amphetamine-induced DA release in the NAc and CPu (Porras et al., 2002). 
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Unpublished data from our laboratory also suggests that a 5-HT2C agonist administered 
into the vmPFC also decreases cocaine hyperlocomotion as well as cocaine-induced Fos 
expression in the dorsolateral caudate-putamen. 
 The 5-HT2A and 5-HT2CR are both G-q protein coupled receptors which activate 
phospholipase C (PLC) and continue their signaling pathway through diacylglycerol 
(DAG), inositol triphosphate (IP3), and protein kinase C (PKC), to increase calcium 
(Ca2+) release. These receptors share approximately 51% of their amino acid sequences 
(Hoyer, Hannon, & Martin, 2002), making them fairly homologous in structure, though 
there are some differences in their localization and signaling properties (Berg et al., 1994; 
Grotewiel & Sanders-Bush, 1999). Both receptors are found throughout the brain 
(Doherty & Pickel, 2000; Pompeiano, Palacios, & Mengod, 1994), but their 
concentrations differ and the 5-HT2AR is also found peripherally, predominantly in the 
digestive tract (Leysen, 2004). Both primarily activate PLC, but also phospholipase A2 
(PLA2), which increases arachidonic (AA) release, and phospholipase D (PLD), which 
increases phosphatidic acid (PA) formation. There are some differences in the degree to 
which these pathways are activated by constitutive activity and ligand binding at the 
receptors (Cunningham et al., 2013). These differences may be due to alterations in the 
receptors over time, as they can undergo trafficking to relocate the receptor on a neuron 
and the 5-HT2CR is the only 5-HT receptor to undergo RNA editing (Niswender et al., 
2001), which may contribute to the different behavioral effects seen when they are 
activated. 
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5-HT2R and Brain Reward Pathway 
The mesolimbic DA system, which includes dopaminergic projections from the 
ventral tegmental area (VTA) to the NAc, plays a critical role in reward learning and is 
certainly involved in addiction, and the mesocortical and nigrostriatal DA systems are 
also implicated (Wise, 2009). The mesocortical DA pathway projects from the VTA to 
the prefrontal cortex (PFC), and the nigrostrial DA pathway projects from the substantia 
nigra (SN) to the CPu. While it was initially thought that the rewarding effects of drugs 
of abuse were due to increased dopamine (DA) in the nucleus accumbens (NAc), research 
has shown that the addiction circuitry is much more complex.  
5-HT affects these DA reward pathways as well (Alex & Pehek, 2007). 5-HT2A and 
5-HT2CRs are found in several regions of the reward circuitry involved in addiction 
(Doherty & Pickel, 2000; Pompeiano, et al., 1994). 5-HT2R manipulations can directly 
influence DA release in the mesolimbic, mesocortical, and nigrostriatal pathways (Alex 
& Pehek, 2007). The nonselective 5-HT2AR agonist, 2,5-dimethoxy-4-iodoamphetamine 
(DOI), has been shown to increase single unit recordings of VTA DA neuron firing as 
well as microdialysis measures of DA release in the PFC, effects which were reversed 
with co-administration of a 5-HT2AR antagonist (Bortolozzi, Diaz-Mataix, Scorza, 
Celada, & Artigas, 2005; Pehek, McFarlane, Maguschak, Price, & Pluto, 2001). 5-HT2AR 
antagonists also decrease cocaine- and amphetamine-induced DA release in the NAc 
(Auclair, Blanc, Glowinski, & Tassin, 2004; Broderick, Olabisi, Rahni, & Zhou, 2004). 
In the nigrostriatal pathway, 5-HT2AR antagonists attenuate phasic DA release in the CPu 
(De Deurwaerdere & Spampinato, 1999; Gobert & Millan, 1999; Ichikawa & Meltzer, 
1995; Lucas & Spampinato, 2000; Porras, et al., 2002; Schmidt, et al., 1992). Conversely, 
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5-HT2CR agonists attenuate both tonic and phasic DA activity (Di Giovanni et al., 1999; 
Di Matteo, Di Giovanni, Di Mascio, & Esposito, 2000; Gobert et al., 2000; Porras, et al., 
2002). For example, a 5-HT2CR agonist decreases VTA DA neuron firing rates (Di 
Giovanni, Di Matteo, Di Mascio, & Esposito, 2000; Di Matteo, et al., 2000) as well as 
DA release in the NAc (De Deurwaerdere & Spampinato, 1999; Di Giovanni, et al., 
1999; Di Matteo, Di Giovanni, Di Mascio, & Esposito, 1999). Further, a 5-HT2CR 
antagonist increases DA release in the PFC (Pozzi, Acconcia, Ceglia, Invernizzi, & 
Samanin, 2002) and cocaine-induced DA in the NAc (De Deurwaerdere, Navailles, Berg, 
Clarke, & Spampinato, 2004). 5-HT2CR inverse agonists also increase DA release in the 
CPu, and this can be reversed with concurrent administration of a 5-HT2CR agonist (Alex, 
Yavanian, McFarlane, Pluto, & Pehek, 2005).  
Aims of Research 
 The goals of the research in this dissertation were to explore the treatment 
potential of 5-HT2R manipulations and to expand upon the knowledge of the localization 
of the effects of systemic 5-HT2R manipulations within the brain reward pathways. In the 
second chapter of this dissertation, I investigated the effects of a 5-HT2AR antagonist in 
the medial subregion of the mPFC on reinstatement of cocaine-seeking behavior. The 
PFC is a key region in the mesocorticolimbic DA pathway and is involved in impulsivity 
and decision-making (Bechara, Damasio, Damasio, & Anderson, 1994; Damasio, 
Grabowski, Frank, Galaburda, & Damasio, 1994; Puumala & Sirvio, 1998). In addiction, 
it is thought that repeated drug taking leads to dysfunction of the PFC in which non-drug 
rewards become less salient and drug rewards become overly salient, thus leading to a 
loss of control and continued drug taking despite consequences (Childress et al., 1999; 
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Goldstein & Volkow, 2002). The medial (m) PFC is further divided into the prelimbic 
(PrL) and infralimbic (IL) regions. The PrL PFC sends projections to the basolateral 
amygdala (BlA) and NAc core, while the IL PFC connects to the CeA via GABA 
inhibitory neurons in intercalated cell masses in the amygdala as well as the NAc shell 
(Brog, Salyapongse, Deutch, & Zahm, 1993; McFarland & Kalivas, 2001; Pare & Smith, 
1993; Sesack, Deutch, Roth, & Bunney, 1989). Similar to their roles in fear conditioning 
(Quirk, Garcia, & Gonzalez-Lima, 2006; Vidal-Gonzalez, Vidal-Gonzalez, Rauch, & 
Quirk, 2006), the PrL PFC is thought to initiate conditioned cocaine-seeking (Kalivas & 
O'Brien, 2008; Peters, Kalivas, & Quirk, 2009), while the IL PFC is necessary for 
extinction of conditioned cocaine-seeking behavior (Peters, et al., 2009). 
Pharmacological inactivation of the PrL PFC attenuates context-, cue-, cocaine-, and 
stress-primed reinstatement as well as cocaine conditioned place preference (CPP) 
(Capriles, Rodaros, Sorge, & Stewart, 2003; Fuchs et al., 2005; Peters, et al., 2009; 
Zavala, Weber, Rice, Alleweireldt, & Neisewander, 2003). Inactivation of the IL PFC 
fails to affect reinstatement of cocaine-seeking (McFarland & Kalivas, 2001), though one 
study showed an increase in cocaine-seeking (Peters, LaLumiere, & Kalivas, 2008); 
however it has also been shown to attenuate cue-primed reinsatement of morphine-
seeking behavior as well (Rocha & Kalivas, 2010).  
Both the PrL and IL regions of the mPFC are densely packed with 5-HT2ARs 
(Doherty & Pickel, 2000; Lopez-Gimenez, Mengod, Palacios, & Vilaro, 1997; 
Pompeiano, et al., 1994), and 5-HT2CRs in these regions have been shown to be involved 
in cue- and cocaine-primed reinstatement (Pentkowski, et al., 2010). My study examined 
the effects of intra-mPFC injections of M100907, a selective 5-HT2AR antagonist, on cue- 
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and cocaine-primed reinstatement as well as locomotor activity and sucrose-seeking 
behavior. This chapter is published in Psychopharmacology.  
In the third chapter of this dissertation, I examined the effects of concurrent 5-
HT2AR antagonism and 5-HT2CR agonism on cocaine hyperlocomotion and cocaine-
induced Fos protein expression in the CPu. Systemically, both 5-HT2AR antagonists and 
5-HT2CR agonists attenuate cocaine hyperlocomotion; we used subthreshold doses of 
each type of ligand, predicting that they would produce a greater effect when given 
together. Research suggests that 5-HT2AR antagonists and 5-HT2CR agonists may have 
therapeutic potential in treating addiction; however since both drugs have side-effects, 
this type of combination therapy may be beneficial in producing a therapeutic effect 
while minimizing potential side effects produced at the respective receptors.  
We measured Fos protein expression in the CPu, as this is the terminal region in 
the nigrostriatal DA pathway involved in motor activity and habitual behaviors (Brown, 
Robertson, & Fibiger, 1992; Naylor & Olley, 1972; White, Doubles, & Rebec, 1998; 
Zimmerberg & Glick, 1974). Some researchers believe that the transition from voluntary 
to habitual drug use is a reflection of a shift of neural control from the ventral to dorsal 
striatum, which includes the CPu in rats (Belin-Rauscent, Everitt, & Belin, 2012; B. J. 
Everitt & Robbins, 2005). After prolonged cocaine self-administration, expected cocaine 
and cue administration increases DA release in the CPu, rather than the ventral striatum 
as in the beginning stages of drug-taking (B. J. Everitt et al., 2008; Ito, Dalley, Howes, 
Robbins, & Everitt, 2000; Ito, Dalley, Robbins, & Everitt, 2002). Additionally, lesions to 
the CPu do not affect cocaine self-administration (Roberts, Koob, Klonoff, & Fibiger, 
1980), but prevent amphetamine-induced stereotypy (Creese & Iversen, 1974; Kelly & 
	   	   	  
11 
Iversen, 1976). In humans, exposure to cues activates the dorsal striatum in experienced 
cocaine addicts (Garavan et al., 2000; Volkow et al., 2006). This chapter of the 
dissertation is published in Synapse.  
 Finally, in chapter 4 I hypothesized that 5-HT2CRs in the amygdala mediate the 
incentive motivational effects of cocaine and cocaine-paired cues. 5-HT2CR agonists 
attenuate cue- and cocaine-primed reinstatement of cocaine-seeking behavior (Fletcher, et 
al., 2008; Neisewander & Acosta, 2007; Pentkowski, et al., 2010) and also increase 
anxiety-like behavior on several paradigms (Nic Dhonnchadha, Bourin, & Hascoet, 
2003). 5-HT2CRs are found throughout the brain (Pompeiano, et al., 1994), including the 
amygdala, a part of the mesolimbic DA pathway known to be involved in reinstatement 
of cocaine-seeking behavior (Alleweireldt, Hobbs, Taylor, & Neisewander, 2006; 
McFarland, Davidge, Lapish, & Kalivas, 2004; See, 2005) as well as stress and anxiety 
(Blanchard & Blanchard, 1972). 
Generally, the amygdala is involved in emotional learning (Bechara et al., 1995) 
and memory (Cahill, 2000), notably the recognition of facial expressions of emotion in 
humans (Adolphs, Tranel, Damasio, & Damasio, 1994; A. W. Young et al., 1995). 
Another role of the amygdala is in regulating fear (Kluver, 1938), in particular Pavlovian 
fear conditioning (Blanchard & Blanchard, 1972; Pribram, Reitz, McNeil, & Spevack, 
1979) and avoidance learning (Weiskrantz, 1956). The amygdala is also involved in 
appetitive conditioning (Cahill & McGaugh, 1990; B. J. Everitt, Morris, O'Brien, & 
Robbins, 1991; Hamann, Ely, Grafton, & Kilts, 1999; Kesner, Walser, & Winzenried, 
1989), which lead to discovering its role in addiction (B. J. C. Everitt, R. N.; Hall, J.; 
Parkinson, J. A.; Robbins, T. W., 2000).  
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The amygdala is made up of distinct nuclei, primarily the basolateral (BlA) and 
central (CeA) regions, which have been differentially implicated in addiction. The BlA is 
highly involved in associating environmental stimuli and reward (B. J. C. Everitt, R. N.; 
Hall, J.; Parkinson, J. A.; Robbins, T. W., 2000). The BlA has an important role in 
reinstatement of cocaine-seeking by drug-associated contextual and discrete cues (B. J. 
Everitt et al., 1999; Fuchs & See, 2002; Fuchs, Weber, Rice, & Neisewander, 2002; 
Kufahl et al., 2009; McLaughlin & See, 2003; Neisewander et al., 2000). The CeA 
projects to brainstem regions to control expression of emotional behaviors (Lanuza, 
Moncho-Bogani, & Ledoux, 2008) and is implicated in stress-reinstatement and primary 
reinforcement effects of cocaine (Koob & Le Moal, 2005; Koob & Nestler, 1997; 
Neisewander, et al., 2000; O'Dell, Sussman, Meyer, & Neisewander, 1999; Wurtz & 
Olds, 1963).  
 To investigate my hypothesis, we examined the effects of a 5-HT2CR agonist 
CP809101 administered directly into the basolateral amygdala (BlA) and the central 
amygdala (CeA) on cue- and cocaine-primed reinstatement of cocaine-seeking behavior. 
We also evaluated the effects of CP809101 in these regions on anxiety-like behavior, as 
5-HT2CR agonists have been shown to affect anxiety (Heisler, Zhou, Bajwa, Hsu, & 
Tecott, 2007; Kimura et al., 2009; Strong, Greenwood, & Fleshner, 2009), and the 
amygdala is an important region in the neurocircuitry of anxiety (M. Davis, 2000).   
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Chapter 2 
Blockade of 5-HT2A Receptors in the mPFC attenuates cue-primed reinstatement of 
cocaine-seeking behavior in rats  
(Master’s thesis, published 2011) 
 Previous work with 5-HT2A selective antagonists found that peripheral 
administration decreases cocaine-induced locomotor activity as well as cue- and cocaine-
primed reinstatement, but has no effect on cocaine self- administration (Fantegrossi, 
Ullrich, Rice, Woods, & Winger, 2002; Filip, Bubar, & Cunningham, 2006; Fletcher, et 
al., 2002; Nic Dhonnchadha, et al., 2009; Orejarena, Lanfumey, Maldonado, & Robledo, 
2010). It is believed that 5-HT action at 5-HT2A receptors may oppose its action at 5-
HT2C receptors (Bubar & Cunningham, 2006; Higgins & Fletcher, 2003). For example, in 
contrast to the inhibitory effects of the 5-HT2A receptor antagonist on cocaine- seeking 
behavior, the 5-HT2C receptor antagonist was found to enhance cocaine-primed 
reinstatement of extinguished cocaine-seeking behavior, as well as cocaine self- 
administration and cocaine-induced locomotor activity (Fletcher, et al., 2002; Nic 
Dhonnchadha, et al., 2009). Furthermore, 5-HT2C receptor agonists inhibit cue-elicited 
and cocaine-primed reinstatement of extinguished cocaine- seeking behavior when 
injected systemically (Fletcher, et al., 2002; Neisewander & Acosta, 2007) or directly 
into the ventral medial prefrontal cortex (vmPFC), which includes the prelimbic and 
infralimbic subregions (Gabbott, Warner, Jays, Salway, & Busby, 2005; Pentkowski, et 
al., 2010). 
 The vmPFC plays a critical role in cue-elicited and cocaine-primed reinstatement of 
extinguished cocaine- seeking behavior, as well as cocaine reinforcement (Di Pietro, 
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Mashhoon, Heaney, Yager, & Kantak, 2008; Goeders & Smith, 1983; McGregor, Baker, 
& Roberts, 1996; Olsen & Duvauchelle, 2006). Exposure to drug-associated cues causes 
an increase in activity-related gene expression in the infralimbic, prelimbic, anterior 
cingulate, and orbitofrontal subregions of the prefrontal cortex (PFC) (Hearing, Miller, 
See, & McGinty, 2008; Kufahl, Zavala, et al., 2009; Neisewander, et al., 2000; Zavala, 
Osredkar, Joyce, & Neisewander, 2008). Furthermore, excitoxic lesions or reversible 
pharmacological inactivation of these subregions of the PFC prevents cue-elicited 
reinstatement of extinguished cocaine-seeking behavior (Di Pietro, Black, & Kantak, 
2006; Fuchs, Evans, Parker, & See, 2004; McLaughlin & See, 2003; Weissenborn, 
Robbins, & Everitt, 1997). Conversely, cocaine injections directly into the mPFC are 
reinforcing (Goeders & Smith, 1983; Guzman, Moscarello, & Ettenberg, 2009) and 
reinstate cocaine self-administration (Goeders, Dworkin, & Smith, 1986). Given our 
recent findings that stimulation of 5-HT2C receptors in the vmPFC attenuates cue-elicited 
and cocaine-primed reinstatement of extinguished cocaine-seeking behavior (Pentkowski, 
et al., 2010) together with research demonstrating opposing roles of 5- HT2C and 5-HT2A 
receptors in modulating cocaine-seeking behavior (Fletcher, et al., 2002; Nic 
Dhonnchadha, et al., 2009), we hypothesized that blockade of 5-HT2A receptors in the 
vmPFC would attenuate cue- and cocaine-primed reinstatement of extinguished cocaine-
seeking behavior. 
 Additional rationale for this hypothesis is that 5-HT2A receptors are densely 
distributed throughout the cortex including the vmPFC, as well as the ventral tegmental 
area (VTA), substantia nigra, and the striatum which have also been implicated in 
addiction (Doherty & Pickel, 2000; Lopez-Gimenez, et al., 1997; Pompeiano, et al., 
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1994). The highly selective 5-HT2A receptor antagonist, M100907, has been shown to 
decrease extracellular dopamine levels in the vmPFC and striatum when infused directly 
into these regions (Pehek, et al., 2001; Schmidt, et al., 1992; Schmidt, et al., 1994). 
Furthermore, elevated glutamate release in the PFC is thought to excite outputs to the 
nucleus accumbens (NAc) resulting in potentiation of cue- and cocaine-primed 
reinstatement of extinguished cocaine-seeking behavior (Di Ciano & Everitt, 2001; 
McFarland, Lapish, & Kalivas, 2003), and increases in glutamate in the vmPFC are 
attenuated by systemic injections of M100907 (Ceglia et al., 2004). These findings are 
consistent with the idea that 5-HT2A receptors in the vmPFC may mediate the inhibitory 
effects of M100907 on cue- and cocaine-primed reinstatement of extinguished cocaine-
seeking behavior. 
This study investigated the hypothesis that 5-HT2A receptor stimulation in the 
vmPFC contributes to the incentive motivational effects of cocaine-conditioned cues and 
cocaine itself. To test this hypothesis, we examined the effects of localized 
microinjections of M100907 on reinstatement of extinguished cocaine-seeking behavior 
elicited by cocaine-paired cues or cocaine-priming injections. The effects of M100907 on 
cocaine self-administration, cue- elicited reinstatement of sucrose-seeking behavior, and 
spontaneous and cocaine-induced locomotor activity were also examined in order to 
assess the specificity of the effects for cocaine-seeking behavior.  
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Methods 
Animals 
Adult male Sprague-Dawley rats weighing 300-325 g at the start of the 
experiments were used in this study.  Animals were housed in a climate-controlled colony 
room with a 12-h reversed light/dark cycle (lights off at 7:00AM) and were cared for in 
accordance with the 'Guide for the Care and Use of Laboratory Animals' (Institute of 
Laboratory Animal Resources on Life Sciences, National Research Council 1996). 
Surgery  
Animals were handled for at least 6 days before implanting catheters into the right 
jugular vein.  Catheters were connected to a bent 22 gauge metal cannula within a plastic 
screw connector (Plastics One, Roanoke, VA) attached to a 10 cm Silastic tube (inner 
diameter 0.012 x outer diameter 0.025 inches, Dow Corning, Midland, MI) with a small 
ball of aquarium sealant ~ 4 cm from the other end.  Animals were anesthetized with 
approximately 3% isoflurane throughout surgery.  Incisions were made in clean, shaven 
areas on the head to expose the skull and on the neck to expose the right jugular vein.  A 
small incision was made in the jugular vein, the catheter was then inserted until flush 
with the ball of aquarium sealant, and the catheter was secured to the vein with sutures on 
either side of the ball.  The catheter was then pulled through a burrow made 
subcutaneously between the two incisions and the rat was then placed into a stereotaxic 
instrument.  Connective tissue was removed from the skull surface and four small screws 
were drilled into the skull to serve as an anchor.  Small holes were then drilled into the 
skull and stainless steel guide cannulae were lowered to a point 1 mm above the targeted 
site of the medial prefrontal cortex (n=59) or the Cg2 region of the anterior cingulate 
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cortex (n=9).  The coordinates for the medial prefrontal cortex were selected based on 
previous research (Filip & Cunningham, 2003; Pentkowski, et al., 2010) and were as 
follows: AP = + 2.7 and ML = +/- 0.75 mm relative to bregma; DV = -3 mm from skull 
surface (Paxinos, 2007). The coordinates for the Cg2 were the following: AP = + 2.0 and 
ML = +/- 0.75 mm relative to bregma; DV = -3 mm from skull surface (Paxinos, 2007).  
The guide cannulae were secured to the skull along with the metal end of the catheter and 
the anchor screws using dental acrylic cement.  Metal stylets were inserted with the 
cannulae during surgery.  All incisions were sutured and treated with a topical antibiotic.  
Catheters were flushed with a solution of 0.1 ml saline containing heparin sodium (70 
U/ml; APP Pharmaceuticals, Schaumburg, IL), Abbokinase (20 mg/ml; ImaRx 
Therapeutics, Tucson, AZ) and Timentin (66.7 mg/ml; GlaxoSmithKline, Research 
Triangle Park, NC) for 5 days after surgery.  Throughout the rest of self-administration 
training and testing, catheters were flushed daily with a solution containing only the 
Timentin and heparin sodium in order to maintain catheter patency.  Animals were given 
at least 7 days of recovery from surgery before beginning self-administration training.  
Catheter patency was tested periodically by administering 0.05 ml Brevital (16.6 mg/ml, 
Jones Pharma Inc., St. Louis, MO), which briefly anesthetizes the animal only if 
delivered i.v. 
Cocaine Self-administration Training 
Cocaine self-administration training took place during daily 2-h sessions, 6 days 
per week.  Animals were trained in operant conditioning chambers (28 x 10 x 20 cm; 
Med Associates, St Albans, Vermont, USA) each containing an active lever, a cue light 4 
cm above the active lever, an inactive lever, a tone generator (500 Hz, 10 dB above 
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ground noise), and a house light on the wall opposite the levers.  Upon pressing the active 
lever to complete a schedule of reinforcement, the light and tone cues were 
simultaneously activated and followed 1 s later by a 0.1 ml cocaine infusion delivered 
over 6 s.   The house light was then activated for a 20-s timeout period, during which 
active lever presses were recorded but had no effects.  Responses on the inactive lever 
were recorded but had no effects.  
 For the first 5 days of training, all animals began on a fixed ratio (FR) 1 schedule 
of reinforcement with the capability to progress to a variable ratio (VR) 2, VR3, and 
finally VR5 schedule.  After ending the session on a VR5 schedule for 5 consecutive 
days, animals then began the remaining sessions on a VR5 schedule.  In this experiment, 
all animals were starting on a VR5 schedule by day 14 and were on a VR5 schedule 
exclusively for at least the last 5 days of self-administration.  All animals were restricted 
to 16 g of food to facilitate acquisition of self-administration (M. E. Carroll, France, & 
Meisch, 1981) and remained food-restricted until they ended on a VR5 schedule for three 
consecutive sessions.  Animals were then given food ad libitum for the rest of the 
experiment.   
Intracranial Drug Infusions 
M100907 (RTI International, Research Triangle Park, NC) was dissolved in 
phosphate buffered saline containing hydrochloric acid, titrated to pH 6.9.  
Microinjections were delivered over a 1-min period using a 30-gauge injector (Plastics 
One) connected via polyethylene 50 tubing (Becton Dickinson, Sparks, MD) to a 25 µl 
syringe (Hamilton Co., Reno, NV) housed in an infusion pump (CMA Microdialysis, 
North Chelmsford, MA). Injection cannulae extended 2 mm below the guide cannulae for 
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the mPFC and 1 mm below for the Cg2.  Successful infusion of the drug was confirmed 
by movement of an air bubble through the drug infusion line.  After the infusion was 
complete, the injectors remained for 1 min to ensure thorough diffusion.  After removing 
the injectors, metal stylets and caps were replaced before the animal was placed into the 
conditioning chamber for the test sessions. 
Cocaine Self-Administration Testing  
 A subset of animals (n=23) with mPFC cannulae were tested for the effects of 
M100907 on cocaine self-administration once they reached a self-administration stability 
criterion of less than 15% variability of infusions per session for 3 consecutive days 
without any upward or downward trends.  Rats were assigned to one of four dose groups 
(0.1, 0.3, 1.0, or 1.5 µg/0.2 µl/side).  All animals were tested twice for self-
administration, once with a vehicle microinjection into the mPFC and once with their 
assigned dose of M100907, with order counterbalanced.  At least 3 additional self-
administration sessions were given in between each test in order to re-establish stable 
self-administration baseline rates.  The bilateral microinjections of M100907 or vehicle 
into the mPFC were administered 5-min before testing.  Three additional sessions of self-
administration were conducted after these tests were completed.  Test sessions lasted for 
2 hours; however data is presented for only the first hour as drug effects do not likely 
persist beyond that time. 
Extinction Phase 
Upon completing self-administration training, and testing if applicable, all 
animals began receiving daily 1-h extinction sessions.  Rats were placed into the self-
administration chambers as before and lever presses were recorded, but produced no 
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consequences (i.e., no infusions or cues were presented).  Catheters were connected to the 
infusion lines during extinction, as well as during all reinstatement tests, even though no 
cocaine was infused.  Extinction sessions continued for 10-14 days and until there was an 
80% reduction in active lever pressing from the animals’ highest response rate during 
extinction or to less than 20 active lever presses. 
Cue Reinstatement of Cocaine-Seeking Behavior 
Following extinction training, a subset of animals with mPFC (n=59) cannulae 
were assigned (or re-assigned if they had undergone self-administration testing) to one of 
four M100907 dose groups (0.1, 0.3, 1.0, or 1.5 µg/0.2 µl/side), counterbalanced based 
on the amount of cocaine intake during self-administration, as this has been shown to 
affect reinstatement response rates (Deroche et al., 1999; Baker et al, 2001).  Another 
subset of animals with anterior cingulate cannulae (n=9) were assigned to receive 
1.5µg/0.2 µl/side M100907 or vehicle.  Animals underwent two tests for the effects of 
M100907 on cue reinstatement of extinguished cocaine-seeking behavior, receiving a 
vehicle microinjection prior to one test and their assigned dose of M100907 prior to the 
other test, with the order of these pretreatments counterbalanced.  Animals were given a 
minimum of 3 extinction days between tests to allow extinction baseline rates to stabilize.  
If animals failed to meet a reinstatement criteria of doubling extinction baseline response 
rates and at least 10 responses on the active lever on both of the 2 test days, they were 
considered ‘nonreinstaters’ and excluded from the analysis.  
Five min after receiving their assigned microinjection, animals were tested for 1 
hr with the same stimulus complex as that paired with cocaine during training available 
response-contingently on an FR 1 schedule; however no cocaine was delivered during 
	   	   	  
21 
cue tests.  The FR 1 schedule was used in place of the VR 5 training schedule because we 
have previously shown that under tests for cue reinstatement the FR1 schedule yields 
higher response rates, and thus greater sensitivity for detecting the predicted decrease, 
than the training schedule (Acosta, Thiel, Sanabria, Browning, & Neisewander, 2008).  A 
noncontingent cue presentation was delivered if the animal did not receive a response-
contingent cue within the first 5 min of the session to minimize the possibility that 
animals would fail to press the lever leaving them unaware that cues were available.   
Cocaine-Primed Reinstatement of Cocaine-Seeking Behavior 
 After the two cue reinstatement tests, a subset of animals with mPFC cannulae 
(n=55) received at least 5 extinction sessions to re-establish a stable baseline extinction 
rate of responding.  They were then given two tests for cocaine-primed reinstatement of 
extinguished cocaine-seeking behavior.  Prior to one test, they received the same dose of 
M100907 as they had received during cue reinstatement testing (0.1, 0.3, 1.0, or 1.5 
µg/0.2 µl/side).  For the other test, they received a vehicle microinjection.  The order of 
the 2 pretreatments was counterbalanced within a group.  Five min after the 
microinjection, animals received a priming injection of cocaine (10 mg/kg, i.p.) and were 
then immediately placed into the conditioning chamber.  Lever presses were recorded, 
but produced no consequences (i.e., no cues or cocaine were delivered).  To control for 
injection stress, animals were given saline i.p. injections on the day preceding their 
cocaine reinstatement tests and the average response rates during these sessions were 
used as the extinction baseline.  Animals were given a minimum of 3 extinction sessions 
between tests to allow extinction baseline rates to stabilize.  If animals failed to meet the 
reinstatement criteria of doubling baseline and at least 10 responses on the active lever 
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during both of the reinstatement tests, they were considered ‘nonreinstaters’ and were 
excluded from the analysis.  All animals were tested for cue reinstatement before cocaine 
reinstatement.   
M100907-Primed Reinstatement of Cocaine-Seeking Behavior 
 After cocaine reinstatement testing, a subset of animals with mPFC cannulae 
(n=44) was given a minimum of 5 extinction sessions to allow extinction baseline 
response rates to stabilize.  Animals were then given two reinstatement tests with a 
microinjection of M100907 (0.1, 0.3, 1.0, or 1.5 µg/0.2 µl/side) prior to one test and 
vehicle prior to the other test, counterbalanced for order of pretreatment.  Animals 
received the same assigned dose of M100907 that they had received for cue and cocaine-
primed reinstatement testing.  Animals were placed into the self-administration chambers 
5 min after the microinjection for a 1-h test.  Responding on neither the active nor the 
inactive lever had any consequences during these test sessions.   
Cue Reinstatement of Sucrose-Seeking Behavior 
After cocaine-primed reinstatement tests, a subset of animals with mPFC 
cannulae (n=10) were food-restricted to approximately 18 g of food/day for two days 
prior to beginning sucrose reinforcement training.  The animals were also given 
approximately 30 sucrose pellets (45 mg, Bio-Serv, Frenchtown, NJ) in their home cage 
to familiarize them with the pellets.  Animals were trained in a different room with a 
different set of operant conditioning chambers than those used for cocaine self-
administration training.  These chambers were each equipped with a food pellet dispenser 
and a food well located between 2 levers.  The location of the active and inactive levers 
from cocaine self-administration was reversed for sucrose reinforcement training.  In all 
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other respects, the training was similar to that used for cocaine self-administration.  Upon 
completion of a schedule of reinforcement, a cue light was presented above the active 
lever that oscillated on for 1 s and off for 1 s for 7 s total and a 45 mg sucrose pellet was 
delivered 1 s after the onset of the light.  The house light remained on during the session 
aside from when the cue light was on as well as a 20-s timeout period after completion of 
a schedule during which active lever presses had no effects.  Rats were given daily 30-
min sessions beginning on an FR 1 schedule of reinforcement with the capability to 
progress to a VR3 and then a VR5 schedule.  Once animals ended the session on a VR5 
schedule, they began the next session on a VR3 schedule.  If they ended on a VR5 
schedule again, they began the next session on a VR5 schedule and stayed on this 
schedule for the remainder of training.  Animals remained food restricted until they ended 
three sessions on a VR5 schedule, at which point they were given food ad libitum for the 
rest of the experiment.  All animals began on a VR5 schedule during the last 7 sessions of 
training and all were given a total of 14 sucrose training sessions.   
Next, animals underwent a total of 14 days of 1-hr extinction training sessions, 
during which there was at least an 80% reduction in lever pressing from the animals’ 
highest response rate during extinction.  Subsequently, animals were tested twice for cue 
reinstatement.  They received a 1.5 µg/0.2µl/side M100907 microinjection prior to one 
test and a vehicle microinjection prior to the other test, counterbalanced for order of 
pretreatment.  5-min after receiving a microinjection, animals were tested for 1-hr with 
the same stimulus complex as was paired with sucrose during training on an FR 1 
schedule; however no sucrose was available.  A noncontingent cue was delivered if a rat 
did not receive a response-contingent cue within the first 5 min of the test session.  
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Animals were given a minimum of 3 extinction sessions between tests to allow extinction 
baseline rates to stabilize. 
Locomotor Activity 
 A subset of animals with mPFC cannulae (n=24) that had a history of cocaine 
intake from the previous experiments were assigned to receive a microinjection of 
M100907 at an effective dose from cue-primed reinstatement testing (1.0 µg/0.2µl/side) 
or vehicle.  For two days before testing, animals received 1-h habituation sessions in the 
locomotor activity chambers. They were then tested twice, receiving either an injection of 
cocaine (10 mg/kg, i.p.) or saline, counterbalanced for order, immediately after receiving 
their assigned microinjection.   Rats were then placed into Plexiglas locomotor chambers 
(44 x 24 x 20 cm high) and were tested for 90 min.  A computer-automated video 
tracking system (Clever Systems, Reston, VA) was used to measure the distance traveled 
by each animal.  Animals were given 5 rest days in their home cages between the two 
tests.  
Statistical Analyses 
Data were analyzed using mixed-factor analyses of variance (ANOVAs) with 
session (e.g. extinction baseline, vehicle test, and M100907 test) as a within-subjects 
factor and dosage group (0.1, 0.3, 1.0, or 1.5 µg/0.2 µl/side) as a between-subject factor.  
A Greenhouse-Geisser correction was used to correct for heterogeneity of variance in the 
data.  Subsequent post-hoc comparisons were made using tests of simple main effects.  In 
addition, planned t-tests were used to test the prediction that cocaine-seeking behavior is 
attenuated after M100907 relative to vehicle pretreatment.  Baseline values were 
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calculated as the average of the two sessions that occurred before each test day (e.g. the 
day before cue testing with M100907 and the day before cue testing with vehicle). 
Histology 
Animals were deeply anesthetized with 3% isoflurane and given intracranial 
infusions (0.2 µl/side) of 1% methylene blue to verify cannulae placements.  Animals 
were then decapitated and the brains were removed, cryoprotected, frozen, and stored at -
20°C.  Brains were sliced in coronal sections (40 µm), stained with thionin, and examined 
under a microscope by observers unaware of group assignment who determined the point 
of drug infusion. 
Timeline of testing and summary of attrition 
 All 68 animals, 59 with mPFC and 9 with Cg2 cannulae, were trained to self-
administer cocaine and underwent extinction training followed by cue reinstatement 
testing. Although this study was conducted using 4 different cohorts of rats, each cohort 
included rats tested at each of the M100907 doses, except for the highest dose which was 
included only in the last cohort.  The cue reinstatement tests were the only tests that 
animals with Cg2 cannulae underwent. During cue reinstatement tests, 2 animals with 
mPFC cannulae and 1 animal with a Cg2 cannula failed to meet reinstatement criteria of 
double baseline or at least 10 lever presses, and so these animals were omitted from the 
data analysis for these tests.  Almost all animals with mPFC cannulae (n=55) underwent 
cocaine-primed reinstatement testing following the cue reinstatement tests, and of these, 
2 animals failed to meet the reinstatement criteria and were omitted from the data 
analyses for these tests.  One animal with mPFC cannulae given the 1.5 µg dose of 
M100907 prior to cocaine-primed reinstatement was considered an outlier (3+ standard 
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deviations above the mean) and was also excluded from the analysis.  A subset of 23 
animals with mPFC cannulae underwent self-administration testing prior to extinction 
training, and a different subset of 10 animals with mPFC cannulae underwent testing for 
cue reinstatement of sucrose-seeking behavior. Finally, 24 animals with mPFC cannulae 
were also tested for the effects of M100907 on locomotor activity after reinstatement 
testing had been completed.    In summary, animals with mPFC cannulae received a total 
of 6 to 8 microinfusions, whereas animals with anterior cingulate cannulae received a 
total of 2 microinfusions. The order of specific test types is summarized in Table 1. 
Results 
Figures 1A and 1B show the representative cannula tip placements for each 
region.  None of the animals had misplaced cannulae. All descriptive statistics given 
below are presented as the mean ± SEM. 
Effects of M100907 on Cocaine Self-Administration 
There was no significant difference between groups for total cocaine intake before 
testing.  The average number of infusions ± SEM across the last 5-days of self-
administration training for the groups ranged from 24.7 ± 0.37 to 29.9 ± 0.72.  Figure 2 
illustrates the effects of mPFC M100907 infusions on the number of reinforcers obtained 
during self-administration testing.  The ANOVA of number of reinforcers/h showed that 
there was a main effect of test day [F(2,38)=5.23, P<0.05] but no main effect of group or 
interaction with test day on self-administration behavior.  When collapsed across doses 
(see Figure 2B) there was a significant decrease in reinforcers obtained on the M100907 
test day versus baseline [t(22)=3.29, P<0.05]. 
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Extinction 
Active and inactive lever presses during the first session of extinction training are 
shown in Table 2.  All animals had at least 13 extinction sessions before reinstatement 
testing began.  For animals with mPFC cannulae, ANOVAs of the number of active and 
inactive lever presses/h on the first day of extinction versus the last day of extinction 
before testing showed main effects of day [F(1,54)=144.70 and 18.79, respectively, 
P<0.01] but no dose effect or interaction with dose.  Similarly for animals with Cg2 
cannulae, the ANOVA of number of active lever presses/h during the first extinction 
session versus the last  extinction session before testing showed only a main effect of day 
[F(1,7)=29.45, P<0.01].  In each case, the main effects indicated a significant drop in 
responding across training sessions.  There were no significant effects for inactive lever 
presses/h in animals with Cg2 cannulae, likely because initial response rates during the 
first sessions were low.  
Effects of M100907 on Cue Reinstatement of Cocaine-Seeking Behavior 
Figure 3 shows the effects of M100907 infusions into mPFC on cue-elicited 
reinstatement of cocaine-seeking behavior.  The ANOVA of responses/h on the active 
lever for animals with mPFC cannulae indicated a significant interaction between test 
session and M100907 dosage group [F(6,104)=2.20, p<0.05].  Tests of simple main 
effects indicated that all groups exhibited cue reinstatement evident as an increase in 
responding on the vehicle pretreatment test day relative to the extinction baseline 
(p<0.05).  In addition, M100907 pretreatment significantly decreased responding in 
animals receiving the 1.0 and 1.5 µg doses relative to their vehicle pretreatment 
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[t(13)=2.00, P<.05 and t(16)=3.56, P<.05, respectively], demonstrating a decrease in cue 
reinstatement at these doses.     
Figure 4 illustrates the effects of M100907 infusions on cue reinstatement of 
cocaine-seeking behavior in animals with Cg2 cannulae.  The ANOVA of responses/h on 
the active lever indicated a significant main effect of test day [F(2,14)=9.242, p<0.05]. 
Tests of simple main effects indicated that animals exhibited cue reinstatement evident as 
an increase in responding on the vehicle pretreatment test day relative to the extinction 
baseline (p<0.05), however there were no significant differences between vehicle and 
M100907 test days.  Table 2 shows inactive lever presses on M100907 test days for all 
groups. There were no significant differences for inactive lever presses. 
Effects of M100907 on Cocaine-Primed Reinstatement of Cocaine-Seeking Behavior 
 Figure 5 illustrates the effects of intra-mPFC infusions of M100907 on cocaine-
primed reinstatement of cocaine-seeking behavior.  There were 2 animals out of 55 that 
failed to meet the reinstatement criteria and were excluded from the analyses.  The 
ANOVA of responses/h on the active lever indicated a significant main effect of test day 
[F(1.6,76.6)=42.2, P<0.001] but no interaction with dose or main effect of dose.  The 
planned comparisons also failed to show any differences between vehicle and M100907 
test days for any of the groups.  Also shown is the main effect of M100907 on cocaine-
primed reinstatement collapsed across all four doses.  Tests of simple main effects 
indicated an increase in responding relative to the extinction baseline on both the vehicle 
and M100907 test days (p<0.001).  There was also a significant decrease in responding 
on M100907 test day compared to vehicle test day (p<0.05).  There were no differences 
in inactive lever presses (see Table 2).  Because these results were contrary to our 
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hypothesis, we examined whether effects occurred during the first 30 min when the drug 
effects should be maximal.  Responses/30 min showed a similar pattern across groups as 
the 1-h analysis (data not shown) with a main effect of test day [F(1.6,78.6)=35.2, 
P<0.001) but no dose or interaction effects. 
Effects of M100907 on Reinstatement of Cocaine-Seeking Behavior 
Figure 6 illustrates that M100907 priming injections infused into mPFC prior to 
testing failed to alter responding relative to extinction baseline.  The ANOVA of 
responses/h indicated that there were no significant effects on response rates on either the 
active or inactive levers (see Table 2).    
Effects of M100907 on Cue Reinstatement of Sucrose-Seeking Behavior 
Figure 7 shows the effects of intra-mPFC infusions of 1.5 µg M100907 on 
reinstatement of sucrose-seeking behavior.  The ANOVA of responses/h on the active 
lever indicated a significant main effect of test day [F(2,18)=6.87, p<0.05] but no 
interaction with dose or main effect of dose. Tests of simple main effects indicated that 
animals exhibited cue reinstatement evident as an increase in responding on the vehicle 
pretreatment test day relative to the extinction baseline (p<0.05), however reinstatement 
was also evident on the M100907 test day and there was no significant difference 
between vehicle and M100907 test days.  There were no differences in inactive lever 
presses (see Table 2). 
Effects of M100907 on Locomotor Activity 
 Figure 8 shows the effects of 1.0 µg/0.2 µl/side M100907 infused into mPFC on 
spontaneous and cocaine-induced locomotor activity.  The ANOVA indicated a 
significant effect of test session [F(1,22)=76.292, P<.05], but no M100907 dose effect or 
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test by dose interaction.  Tests of simple main effects indicated that animals exhibited 
significantly more distance traveled when given cocaine as compared to saline, but there 
was no difference in distance traveled in animals pretreated with vehicle versus 
M100907.  
Discussion
The present findings are the first to demonstrate that a 5-HT2A receptor antagonist 
infused into the mPFC dose-dependently decreases cue-elicited reinstatement of cocaine-
seeking behavior.  These results are consistent with the findings that peripheral injections 
of M100907 attenuate cue-elicited reinstatement of cocaine-seeking behavior (Nic 
Dhonnchadha, 2009).  Furthermore, the findings support our hypothesis that stimulation 
of 5-HT2A receptors in the mPFC modulates incentive motivational effects of cocaine-
paired cues.  In contrast to the effects on cue reinstatement, intra-mPFC infusions of 
M100907 failed to dose-dependently alter cocaine self-administration or cocaine-primed 
reinstatement.  There appeared to be a mild attenuation of these behaviors as there was a 
main effect of test day in both cases; however, there was no significant difference 
between numbers of reinforcers obtained or number of active lever presses following 
vehicle pretreatment relative to M100907 pretreatment at any given dose of M100907.  
For this reason, we suggest that the attenuation of both cocaine self-administration and 
cocaine-primed reinstatement that was detected when the data were collapsed across dose 
(i.e., main effect of test day) is likely due to some nonspecific effect rather than 
antagonism of 5-HT2A receptors.  The lack of effect of M100907 on cocaine self-
administration was expected given that systemic administration of M100907 does not 
affect this behavior (Nic Dhonnchadha, 2009; Fletcher et al, 2002).  In contrast, we had 
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predicted that M100907 infusions into mPFC would attenuate cocaine-primed 
reinstatement, similar to its systemic effects (Nic Dhonnchadha, 2009; Fletcher et al, 
2002). 
Out control manipulations provide support for the anatomical and behavioral 
selectivity of M100907 effects on cue reinstatement.  For instance, intra-mPFC infusions 
of M100907 did not alter spontaneous or cocaine-induced locomotor activity at the 1.0 
µg dose, which was a dose that effectively reduced cue reinstatement, suggesting the 
latter effect was not due to motor impairment.  Furthermore, the higher effective dose of 
1.5 µg/side did not affect cue reinstatement of sucrose-seeking behavior.  These findings 
further mitigate the possibility that the infusions interfered with the animals' ability to 
respond and also suggest that memory was intact.   The 1.5 µg/side M100907 infusions 
into the neighboring Cg2 subregion of the anterior cingulate cortex failed to alter cue 
reinstatement, suggesting anatomical specificity of the mPFC infusions. 
It seems likely that the attenuating effect of M100907 on cue reinstatement was 
due to the antagonism of 5-HT2A receptors in the mPFC.  M100907 has a >1000-fold 
selectivity for 5-HT2A receptors vs. 5-HT2C receptors (Kehne et al., 1996) and several 
studies have demonstrated that doses of 0.005-0.4 mg/kg M100907 reverse the behavioral 
effects of 5-HT2A, but not 5-HT2C, receptor agonists (Dekeyne, Girardon, & Millan, 
1999; Gresch, Barrett, Sanders-Bush, & Smith, 2007; Hitchcock, Lister, Fischer, & 
Wettstein, 1997; McCreary, Filip, & Cunningham, 2003; Vickers et al., 2001; Wettstein, 
Host, & Hitchcock, 1999).  We chose not to investigate the effects of a 5-HT2A agonist in 
the present study because these drugs have hallucinogenic effects, which would cloud 
interpretation.  If M100907 was acting on another receptor subtype, the most likely 
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candidate is the closely related 5-HT2C receptor.  This is unlikely, however, because prior 
research has shown that peripheral injections of the selective 5-HT2C receptor antagonist 
SB242084 do not affect cue reinstatement (Burbassi & Cervo, 2008; Burmeister, et al., 
2004), and in fact, this antagonist reverses the attenuation of cue reinstatement observed 
with 5-HT2C receptor agonists and enhances cocaine-primed reinstatement (Burmeister, et 
al., 2004; Fletcher, et al., 2002; Neisewander & Acosta, 2007).  Furthermore, SB242084 
infused into the mPFC has no effect on cue- or cocaine-primed reinstatement, whereas 
the selective 5-HT2C agonist MK212 attenuates both behaviors (Pentkowski, et al., 2010).  
Thus even though it is doubtful M100907 infusions antagonized 5-HT2C receptors, if such 
an effect had occurred that may explain why only attenuation, and not complete reversal, 
of cue reinstatement was observed.  Specifically, as the dose of M100907 is increased, 
antagonism of additional 5-HT2A receptor may be accompanied by antagonism of 5-HT2C 
receptors with the latter functionally opposing any additional reduction of cue 
reinstatement by 5-HT2A receptor antagonism. 
The region-specific effect of M100907 in attenuating cue reinstatement is 
consistent with literature suggesting that the mPFC plays a critical role in drug abuse-
related behavior.  It is thought that repeated psychostimulant administration decreases 
activity in the PFC, resulting in compulsive drug taking behavior (Jentsch & Taylor, 
1999; Volkow, Fowler, Wang, & Goldstein, 2002).  Although activation of mPFC may be 
reduced in drug-dependent individuals relative to controls, when drug-experienced 
humans or rats are exposed to drug-associated cues, the PFC exhibits increased activity 
(Childress, et al., 1999; Ciccocioppo, Sanna, & Weiss, 2001; Grant et al., 1996; Maas et 
al., 1998; Neisewander, et al., 2000).  Furthermore, the mPFC has been shown to be 
	   	   	  
33 
involved in the incentive motivational effects of drug-paired cues through other 
pharmacological manipulations as well (Bossert, Ghitza, Lu, Epstein, & Shaham, 2005; 
Kalivas & McFarland, 2003; McLaughlin & See, 2003).   
Our findings that only cue and not cocaine-primed reinstatement was affected by 
mPFC infusion of M100907 suggest the intriguing possibility that different mechanisms 
within the mPFC may be involved in these types of reinstatement.  It has been 
hypothesized that there is a "final common pathway" for the neurocircuitry involved in 
stress-, cocaine-, and cue-primed reinstatement (Capriles, et al., 2003; Kalivas, 2008; 
Neisewander, et al., 2000) that likely involves glutamateric projections from the mPFC to 
the NAc (Feltenstein & See, 2008; Kalivas & McFarland, 2003; Kalivas, Peters, & 
Knackstedt, 2006; Shaham, Shalev, Lu, De Wit, & Stewart, 2003).  To our knowledge, 
this study is the first to find differential effects of a given manipulation of the mPFC 
across the different types of reinstatement, suggesting that there may be independent 
circuitries involving the mPFC that mediate the effects of cue and cocaine-primed 
reinstatement.   This hypothesis is equivocal presently, however, given that the general 
attenuation of cocaine-primed reinstatement by M100907 does not allow us to completely 
rule out the possibility of mPFC 5-HT2A receptor involvement in the incentive 
motivational effects of cocaine priming.  Indeed it is possible that cocaine-primed 
reinstatement may be altered at different doses of either the cocaine prime or intra-mPFC 
M100907 infusions.  It should be noted that the doses used in the present study were 
based on previous literature indicating behavioral effects of intracranial infusions 
approximating the dose range.  For instance, microinjections of M100907 into the VTA 
attenuate cocaine-induced (10 mg/kg) locomotor activity at doses lower (0.1-0.3 µg/0.2 
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µl/side) than those we found to be effective (McMahon, et al., 2001).  Further, infusions 
of 0.1-0.5 µg M100907 into the NAc were found to decrease impulsive responding on a 
5-choice serial reaction time task, though the higher dose was thought to possibly impair 
the animals’ functioning on the task (Robinson et al., 2008).  Thus, the doses of M100907 
that we tested were within an effective range based on localized infusions into other 
regions; however this drug has not been used extensively for intracranial injections so we 
cannot rule out the possibility that effects may occur at lower or higher doses.   
Other possible reasons for the lack of M100907 effects on behaviors were 
considered.  For instance, we believe it is unlikely that tolerance to M100907 occurred 
with repeated administration based on our unpublished observation that 1.0 µg M100907 
significantly attenuated headshakes induced by the 5-HT2A receptor agonist DOI after 
animals had undergone three other test phases (M100907-, cue- and cocaine-primed 
reinstatement testing).  We also found no effect of M100907 on cocaine-primed 
reinstatement during the first 30 minutes of testing, so it is unlikely that M100907 effects 
were obscured by testing beyond a period of maximal drug levels.  Finally, while we did 
not observe any effects of M100907 on cue reinstatement of sucrose-seeking behavior, 
our data cannot completely rule out the possibility that the mPFC is involved in the 
incentive motivational effects of other reinforcers given the difficulties of equating the 
motivational value of the different reinforcers.  Thus, it will be important to further test 
the role of mPFC 5-HT2A receptors in order to draw firm conclusions as to whether these 
receptors modulate the incentive motivational effects of cocaine priming injections and/or 
sucrose-associated cues.  Presently it appears that at the very least, 5-HT2A receptors in 
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mPFC may be more sensitive to modulating motivational effects of cocaine-associated 
cues relative to other cocaine-related behaviors. 
Future research will be needed to determine the specific neuroanatomical 
pathways involved in the attenuation of cue-elicited reinstatement of cocaine-seeking 
behavior that we observed in this study.  In the mPFC, 5-HT2A receptors are located 
postsynaptically, primarily on apical dendrites of pyramidal neurons with a minority 
found on GABA interneurons (Cornea-Hebert, Riad, Wu, Singh, & Descarries, 1999; 
Hamada et al., 1998; Jakab & Goldman-Rakic, 1998; Santana, Bortolozzi, Serrats, 
Mengod, & Artigas, 2004; Willins, Deutch, & Roth, 1997).  5-HT has an excitatory effect 
on glutamate release from pyramidal cells originating in the mPFC (Aghajanian & 
Marek, 1997).  Studies showing activation of the mPFC by cocaine-paired cues 
(Childress, et al., 1999; Grant, et al., 1996; Kilts et al., 2001) and attenuation of cue-
primed reinstatement of cocaine-seeking behavior by an α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) antagonist in the NAc core (Di Ciano & Everitt, 2001) 
have lead to the hypothesis that glutamate transmission from the PFC to NAc core is 
involved in reinstatement (McFarland, et al., 2003).   Therefore, one potential effect of 
blocking 5-HT2A receptors in the mPFC is a decrease in the activity of glutamatergic 
projection neurons to the VTA and NAc. 
Another potential mechanism for M100907 effects is via modulation of 
dopamine, as 5-HT2A receptor antagonism decreases mesocortical dopamine release 
(Alex & Pehek, 2007) and is thought to inhibit excitatory inputs from the mPFC to the 
VTA (Vazquez-Borsetti, Cortes, & Artigas, 2009).  Furthermore, systemic injections 
have shown that M100907 attenuates DOI-elicited increases in dopamine in the mPFC 
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(Gobert & Millan, 1999; Pehek, et al., 2001) and dorsal raphe stimulated release of 
dopamine in the NAc (De Deurwaerdere & Spampinato, 1999).  These findings lead to 
the conclusion that 5-HT2A receptors in the mPFC modulate phasic, but not tonic, 
dopamine release in the mPFC and striatum (De Deurwaerdere & Spampinato, 1999; 
Gobert & Millan, 1999; Lucas & Spampinato, 2000; Zhang et al., 2000).  Blocking 5-
HT2A receptors in the mPFC may decrease activation of excitatory projections to the 
VTA, thereby attenuating glutamate receptor stimulation in the VTA and decreasing 
dopamine release in the PFC and NAc (Alex & Pehek, 2007). 
Overall, our results indicate that selectively blocking 5-HT2A receptors in the 
mPFC dose-dependently reduced cue-elicited reinstatement of drug-seeking behavior.  
The lack of a dose-dependent effect of M100907 on cocaine self-administration and 
cocaine-primed reinstatement of cocaine-seeking behavior suggests that the attenuation 
of these behaviors regardless of M100907 dose is not likely receptor-mediated.  Further, 
M100907 in the mPFC did not affect locomotor activity or cue reinstatement of sucrose-
seeking behavior, suggesting the effects on cue reinstatement were not due to general 
performance or a memory deficit.  Therefore, we conclude that 5-HT2A receptors in the 
mPFC play a role in mediating the incentive motivational effects of cocaine-paired cues.  
The findings contribute novel information about the neural circuitry underlying the 
incentive motivational effects of cocaine cues and further suggest that 5-HT2A receptor 
blockade may be a potential therapeutic mechanism to treat cocaine craving and relapse.   
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Chapter 3 
Interaction between 5-HT2A receptor blockade and 5-HT2C receptor activation on 
cocaine hyperlocomotion and Fos protein activation in the caudate-putamen 
(Published in Synapse, 2012) 
Structurally, 5-HT2C and 5-HT2ARs are very similar (Hoyer, et al., 2002; Raymond et 
al., 2001), and are found to coexist in many brain regions involved in addiction circuitry 
(Bubar & Cunningham, 2007; Doherty & Pickel, 2000; Pompeiano, et al., 1994), 
including the mesolimbic pathway originating in the ventral tegmental area (VTA) and 
projecting to nucleus accumbens (NAc) and the nigrostriatal pathway originating in the 
substantia nigra (SN) and projecting to the caudate-putamen (CPu). Functionally, 5-HT2A 
and 5-HT2CRs play opposing facilitative and inhibitory roles, respectively, in cocaine-
related behaviors. For instance, peripheral injections of the 5-HT2AR selective antagonist 
M100907 decrease cocaine hyperlocomotion (Fletcher, et al., 2002; McMahon, et al., 
2001) as well as cue- and cocaine-primed reinstatement of cocaine-seeking behavior, but 
have no effect on cocaine self-administration (Fletcher, et al., 2002; Nic Dhonnchadha, et 
al., 2009). Systemic administration of M100907 also attenuates cocaine discriminative 
stimulus effects (McMahon, et al., 2001). Further, systemic or intra-striatal injections of 
M100907 attenuate MDMA- and amphetamine-induced DA release in the NAc and CPu 
(Porras, et al., 2002; Schmidt, et al., 1992; Schmidt, et al., 1994). Conversely, a selective 
5-HT2CR antagonist enhances cocaine hyperlocomotion as well as cocaine-primed 
reinstatement and cocaine self-administration (Fletcher, et al., 2002; McMahon, et al., 
2001). 5-HT2CR agonists RO-60-0175 and MK212 inhibit cue- and cocaine-primed 
reinstatement of cocaine-seeking behavior, effects that are blocked by pre-administration 
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of 5-HT2CR antagonists, indicating that they are 5-HT2CR-mediated (Fletcher, et al., 
2008; Neisewander & Acosta, 2007; Pentkowski, et al., 2010). Systemic administration 
of 5-HT2CR antagonists has been found to increase amphetamine-induced DA release in 
the NAc and CPu (Porras, et al., 2002), while agonists attenuate morphine-induced DA 
release in the NAc (Willins & Meltzer, 1998).  
Despite the oppositional relationship between behavioral effects mediated by 5-HT2A 
versus 5-HT2CRs, to date, no research has investigated a potential interaction between 
these two receptor subtypes. By contrast, behavioral pharmacology studies of the DA 
system have revealed that interactions between D1-like and D2-likeR families mediate 
effects of psychostimulants. For instance, D2R-mediated stereotypy is observed only 
when there is also tonic stimulation of D1Rs, even though stimulation of D1Rs alone has 
little, if any, effect (Missale, Nash, Robinson, Jaber, & Caron, 1998). Furthermore, D1 
and D2R antagonists synergistically decrease discriminative stimulus properties of 
cocaine and amphetamine (Callahan, Appel, & Cunningham, 1991), and D1 and D2R 
agonists administered together produce qualitatively more intense stereotypy than either 
one alone (Feldman, 1997; Jackson & Westlind-Danielsson, 1994). Investigating whether 
similar interactions exist between the 5-HT2A and 5-HT2CRs is an important research 
question that may suggest a novel approach to developing treatments for psychostimulant 
dependence (Whitten, 2007). 
One way to examine potential interactive effects of 5-HT2AR antagonists and 5-
HT2CR agonists is by measuring Fos activation. Fos protein expression is a commonly 
used measure of functional neuronal activity (Harlan & Garcia, 1998; Herrera & 
Robertson, 1996). Region-specific patterns of Fos expression are associated with acute 
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cocaine administration (Robertson, Paul, Moratalla, & Graybiel, 1991; Torres & Rivier, 
1994; Zahm et al., 2010) and exposure to cocaine-paired cues (Kufahl, Zavala, et al., 
2009; Neisewander, et al., 2000; Zavala, Biswas, Harlan, & Neisewander, 2007) or a 
cocaine-associated context (Brown, et al., 1992; Crawford, McDougall, Bolanos, Hall, & 
Berger, 1995; Hamlin, Clemens, & McNally, 2008; Hotsenpiller, Horak, & Wolf, 2002). 
The 5-HT2AR antagonist, M100907, has been found to decrease cocaine-induced Fos 
expression in the NAc shell and CPu (Szucs, et al., 2005). On the other hand, 5-HT2CR 
antagonists enhance Fos expression in the subthalamic nucleus and CPu (De 
Deurwaerdere, Le Moine, & Chesselet, 2010). We have also found that a 5-HT2C agonist 
administered into the ventromedial PFC decreases cocaine hyperlocomotion as well as 
cocaine-induced Fos expression in the dorsolateral CPu (Pentkowski, et al., 2010; 
Pockros, Pentkowski, Weber, & Neisewander, 2011). Thus, it seems that 5-HT2A 
antagonists and 5-HT2C agonists both decrease cocaine-induced Fos expression in the 
CPu, as well as attenuate cocaine hyperlocomotion. 
In the present study, we hypothesized that concurrent 5-HT2A antagonism and 5-HT2C 
agonism would interact to attenuate the effects of cocaine on locomotion and Fos 
expression. We first examined dose-dependent decreases in cocaine hyperlocomotion by 
M100907 and MK212 given alone. From these experiments, we identified subthreshold 
doses of each drug that produced no effect on cocaine hyperlocomotion when given 
alone. We then tested the effects of a combination of these subthreshold doses of 
M100907 and MK212 on cocaine-induced and spontaneous locomotion. We also 
conducted Fos immunohistochemistry in several brain regions to investigate the effects of 
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concurrent 5-HT2A antagonism and 5-HT2C agonism on cocaine-induced neuronal 
activation. 
Methods 
Animals  
Adult male Sprague–Dawley rats weighing 250–350 g at the start of the experiments 
were used in this study. Animals were housed in a climate-controlled colony room with a 
14-h reversed light/dark cycle (lights off at 7:00 a.m. and on at 9 p.m.) and were cared for 
in accordance with the “Guide for the Care and Use of Laboratory Animals” (Institute of 
Laboratory Animal Resources on Life Sciences, National Research Council 1996).  The 
animals were given food and water ad libitum except during the testing sessions. 
Drugs 
 M100907 (RTI International, Research Triangle Park, NC, USA) and MK212 
(Tocris Cookson Inc., Ellisville, Missouri, USA) were dissolved in a 0.9% saline 
containing 3% tween. Cocaine-HCl (RTI International, Research Triangle Park, NC, 
USA) was dissolved in 0.9% saline. Euthasol (Hospira, Lake Forest, IL, USA) was used 
to deeply anesthetize animals before perfusions. 
General procedures 
 Animals were handled daily for 1 week and were given saline injections to 
habituate them to injection stress on each of the 2 days prior to the start of the 
experiments. All animals were tested in Plexiglas locomotor activity chambers (44 × 24 × 
20 cm high) in a soundproof, dimly lit room for 60-min sessions. A computer-automated 
video tracking system (Clever Systems, Reston, VA, USA) used the orientation of the 
animal’s body (e.g. center of body) to measure the total horizontal distance traveled. All 
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testing was conducted during the animals’ dark cycles.  In experiments testing cocaine 
hyperlocomotion, animals were placed into the test chambers for 1 h prior to any drug 
injections in order for them to habituation to the chamber, thus providing a low baseline 
level of locomotion from which to detect cocaine-induced increases. 
Dose-dependent effects of M100907 and MK212 on cocaine hyperlocomotion  
 Separate cohorts of animals were randomly assigned to groups that received i.p. 
injections of either M100907 (0.025, 0.05, or 0.1 mg/kg) or MK212 (0.125, 0.25, or 0.5 
mg/kg) (n=8/dose) prior to one test; both cohorts received vehicle prior to the other test 
with the order of the drug versus vehicle tests counterbalanced within groups. Following 
habituation on the test day, the animals were given an injection of their assigned drug, put 
back into their home cage for 5-min, and then given an injection of cocaine (15 mg/kg, 
i.p.) immediately before being placed back into the test chambers for the 1-h test. 
Effects of M100907 + MK212 on cocaine hyperlocomotion  
Subthreshold doses of M100907 (0.025 mg/kg, i.p.) and MK212 (0.125 mg/kg, 
i.p.) that failed to alter cocaine-induced locomotor activity on their own in the above 
experiments were then combined as a cocktail to examine potential receptor interactions. 
Animals were randomly assigned to receive 2 drug injections given 5 min apart following 
the habituation period as follows, respectively: saline + saline, saline + cocaine (15 
mg/kg, i.p.), 0.025 mg/kg M100907 + cocaine, 0.125 mg/kg MK212 + cocaine, or 
cocktail + cocaine (n=6-7/group). Rats were placed into their home cage following the 
first injection and were placed back into the locomotor activity chambers for a 1-h test 
following the second injection. This experiment utilized a between-subjects design, as 
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animals were sacrificed after testing and their brains were extracted for Fos analysis as 
described below.  
Effects of M100907 + MK212 on spontaneous locomotion 
Drug-naïve rats were randomly assigned to receive saline, M100907 (0.025 
mg/kg, i.p.), MK212 (0.125 mg/kg, i.p.) or a cocktail of the latter two drugs. Five min 
after injection of their assigned drug, the rats were placed into the locomotor activity 
chambers for a 1-h test. There was no habituation period in this experiment in order to 
avoid having a floor effect that would obviate detection of drug effects on locomotion. 
Tissue preparation 
 To allow 90-min after drug injections for optimum Fos expression, animals 
remained uninterrupted in the locomotor chambers for 30-min after the 1-h test. They 
were then deeply anesthetized with Euthasol (100 mg/kg, i.p.) and perfused transcardially 
with 300 ml of ice-cold 0.1 M phosphate-buffered saline (PBS), pH 7.4, followed by 300 
ml of ice-cold 4% paraformaldehyde in 0.1 M PBS, pH 7.4. The brains were removed, 
postfixed overnight at 4 °C in 4% paraformaldehyde, and then transferred to 15% sucrose 
for 24 h and then to 30% sucrose for an additional 24 h while continuously being stored 
at 4 °C. Coronal sections (40 µm) were collected using a freezing microtome at levels 
corresponding to 3.2, 1.6, 2.56, 5.6 mm relative to bregma (Paxinos and Watson, 1998). 
The tissue sections were then frozen and stored at 20 °C in a cryoprotectant solution 
comprised of 0.02 M PBS (pH 7.2), 30% sucrose, 10% polyvinyl pyrrolidone, and 30% 
ethylene glycol. 
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Fos protein immunohistochemistry 
Tissue sections were first washed in 0.1 M PBS (6×10 min) to remove the 
cryoprotectant. Sections were then incubated in 0.3% H2O2 for 30 min and rinsed with 
0.1 M PBS (3×10 min), followed by incubation in 0.1 M PBS containing 5% normal goat 
serum (NGS) (Vector Laboratories, Burlingame, CA, USA) and 0.2% Triton X-100 
(Sigma, St. Louis, MO, USA) for 1 h. Sections were then incubated for 48 h at 4 °C in 
0.1 M PBS containing anti-Fos rabbit polyclonal antibody (SC-52; 1:2,000; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), 0.1% Triton X-100 and 1% NGS, and then rinsed 
in 0.1 M PBS (3×10 min). Sections were then incubated in 0.1 M PBS containing 
biotinylated goat anti-rabbit IgG (1:500; Vector Laboratories, Burlingame, CA, USA) 
and 1% NGS for 1 h, and then rinsed in 0.1 M PBS (3×10 min). Subsequently, 
horseradish peroxidase activity was visualized with nickel diaminobenzidine and glucose 
oxidase reaction as described in Dielenberg et al. (2001). This reaction was terminated 
after 10 min by rinsing the tissue in 0.1 M PBS (3×10 min). Sections were then mounted 
onto gelatin-coated slides, dried, and dehydrated before cover slipping. 
Fos immunoreactivity analysis 
 Sections were taken at +3.2 mm, which contained the prelimbic (PrL) and 
infralimbic (IL) cortices; sections taken at +1.6 mm contained the NAc core (NAcC) and 
shell (NAcS), and the dorsolateral CPu. Care was taken to ensure that the sections that 
were labeled came from the same anatomical level within each plane for each subject. 
Quantification of Fos immunoreactivity was examined using a Nikon Eclipse E600 
(Nikon Instruments, Melville, NY, USA) microscope set at 20X. For all regions, the 
sample area counted was 0.26 mm2 and there were a total of six sample areas counted for 
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each subject (i.e., 1 sample area/2 hemispheres/3 sections) that were then averaged to 
provide a mean number of immunoreactive cells per sample area. An observer blind to 
treatment conditions identified Fos immunoreactivity as a blue-black oval-shaped nucleus 
distinguishable from background using size and optical density criteria set using the 
Image Tool software package (Version 3.0, University of Texas Health Sciences Center, 
San Antonio, TX, USA). Regions analyzed and representative sample areas are shown in 
Figure 9. These images were captured using SPOT Advanced software (Version 3.5 
Sterling Heights, MI, USA) and no modifications were made to the images. 
Statistical analyses 
Because the purpose of the dose-effect experiments was to identify subthreshold 
doses of M100907 and MK212, locomotor activity data at each dose were analyzed 
separately using repeated measures analyses of variance (ANOVAs) with time (e.g. 15-
min time bins) and test (e.g. saline or cocaine) as within-subject factors. For drug 
interaction experiments, spontaneous and cocaine-induced locomotor activity data were 
analyzed using mixed-factor ANOVAs with time as a repeated measure within-subject 
factor and drug group as a between-subject factor. For all tests of cocaine 
hyperlocomotion, the last 15-min of habituation served as a baseline. Fos data were 
analyzed by region using one-way ANOVAs with drug as a between-subject factor. In 
order to focus analyses of Fos on group differences in response to cocaine standardized 
across regions, raw data was converted to a percent of saline control and analyzed using 
one-way ANOVAs with drug as a between-subject factor. A Greenhouse–Geisser 
correction was used to correct for heterogeneity of variance in the data. Significant 
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effects were further analyzed using smaller ANOVAs and post hoc comparisons were 
made using Tukey’s HSD test. All statistics were run using SPSS, version 20. 
Results 
Dose-Effect Function of M100907 on Cocaine Hyperlocomotion 
Figure 10 shows the dose-effect function of M100907 on cocaine 
hyperlocomotion. For the lowest dose of 0.025 mg/kg, the ANOVA of distance traveled 
showed a main effect of time [F(1.51,10.60)=10.92, p<0.01], but no effect of test nor test 
by time interaction demonstrating that locomotion was similar regardless of vehicle 
versus M100907 treatment. Post hoc tests on the main effect of time showed that cocaine 
increased locomotor activity relative to baseline, and locomotor activity remained 
elevated for the first 30-min of testing (p<0.05). 
For the 0.05 mg/kg dose, the ANOVA of distance traveled showed an interaction 
of time by test [F(4,28)=3.30, p<0.05], as well as a main effect of time 
[F(1.76,12.33)=9.06, p<0.01]. Post hoc tests showed a difference between baseline and 
the first 15-min of testing only when animals were pretreated with vehicle (p<0.05). On 
the vehicle test day, locomotor activity remained elevated at the 30-min time point 
compared to baseline (p<0.05). On the M100907 test day, there was no difference 
between any of the time points, consistent with a failure to observe cocaine 
hyperlocomotion. However, the M100907 attenuation of cocaine hyperlocomotion was 
not due to a change at a particular time as there were no differences between test days 
any time points.  
For the 0.1 mg/kg dose, the ANOVA of distance traveled showed a main effect of 
time [F(4,28)=14.69, p<0.01] as well as a main effect of test [F(1,7)=9.06, p<0.05], with 
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the latter indicating less distance traveled overall during the M100907 test than during the 
vehicle test. Post hoc tests on the main effect of time showed that cocaine increased 
locomotor activity relative to baseline for the first 15-min of testing regardless of 
pretreatment (p<0.01). Collectively, these findings suggest that cocaine hyperlocomotion 
was slightly attenuated at this dose of M100907. 
Dose-Effect Function of MK212 on Cocaine Hyperlocomotion 
 Figure 11 shows the effects of MK212 on cocaine hyperlocomotion. For the 
lowest dose of 0.125 mg/kg, the ANOVA of distance traveled showed a main effect of 
time [F(4,28)=35.95, p<0.01], but no effect of test nor test by time interaction 
demonstrating that locomotion was similar regardless of vehicle versus MK212 
treatment. Post hoc tests on the main effect of time showed that cocaine increased 
locomotor activity relative to baseline, and locomotor activity remained elevated for 45 
min regardless of test day (p<0.05). 
For the 0.25 mg/kg dose, the ANOVA of distance traveled showed an interaction 
of time by test [F(4,28)=3.40, p<0.05], as well as a main effect of time [F(4,28)=23.17, 
p<0.01], and a main effect of test [F(1,7)=17.07, p<0.01). Post hoc tests showed a 
difference between baseline and the first 15 min of testing on both test days (p<0.05). On 
the vehicle test day only, locomotor activity remained elevated at the 30-min time point 
compared to baseline (p<0.05). There was also a significant difference between vehicle 
and MK212 test days at the 30-min time point (p<0.05). 
For the 0.5 mg/kg dose, the ANOVA of distance traveled showed an interaction 
of time by test [F(4,28)=11.77, p<0.01], as well as a main effect of time [F(4,28)=37.35, 
p<0.01], and a main effect of test [F(1,7)=9.98, p<0.05]. Post hoc tests showed a 
	   	   	  
47 
difference between baseline and the first 15 min of testing on the vehicle test day 
(p<0.05), and locomotor activity remained elevated compared to baseline (p<0.05) until 
the last 15-min of the test. On the MK212 test day, there was no difference between 
baseline and the first 15-min of testing, however there was a significant decrease in 
activity compared to baseline at all other time points (p<0.05). There were also 
significant differences between vehicle and MK212 test days at the last three time points 
(p<0.05). 
M100907/MK212 Interaction Effects on Cocaine Hyperlocomotion  
 The effects of the M100907/MK212 cocktail on cocaine-induced locomotor 
activity are shown in Figure 12. The ANOVA of distance traveled showed a significant 
time by drug interaction [F(6.95,45.20)=2.49, p<0.05] as well as a main effect of time 
[F(1.74, 45.20)=40.29, p<0.01] and a main effect of drug [F(4,26)=4.97, p<0.01]. Post-
hoc comparisons indicated a significant difference between the saline + saline and saline 
+ cocaine groups (p<0.05, Tukey HSD), as well as the saline + cocaine and cocktail + 
cocaine groups (p<0.01, Tukey HSD). There were no differences between the cocaine + 
saline and cocaine + M100907 or cocaine + MK212 groups (p=0.474 and p=0.463, 
respectively). 
At each 15-min time-bin during testing, the one-way ANOVAs of distance 
traveled showed a significant effect of drug group [Fs(4,30)=5.491-3.751, p<0.05]. 
Across all post-cocaine time bins, the cocktail + cocaine group exhibited less locomotion 
than the saline + cocaine group (p<0.05, Tukey HSD), whereas the saline + saline group 
exhibited less locomotion at the 30 (p<0.01, Tukey HSD) and 60 min time bins only 
(p<0.05, Tukey HSD). In contrast, the M100907 + cocaine and MK212 + cocaine groups 
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did not differ from either the saline + saline or saline + cocaine groups at any time point. 
There was no difference in baseline between groups. 
M100907/MK212 Interaction Effects on Spontaneous Locomotion  
The effects of the M100907/MK212 cocktail on spontaneous locomotor activity 
are shown in Figure 13. The ANOVA of distance traveled showed a main effect of time 
[F(3,84)=138.551, p<0.01], but no effect of drug or drug by time interaction, suggesting 
that none of the drug treatments altered spontaneous locomotion. Post-hoc tests showed a 
difference between the first 15-min and each of the 30-min, 45-min, and 60-min time 
points (p<0.01), as well as a difference between the 30-min and 45-min time points 
(p<0.01). 
M100907/MK212 Interaction Effects on Cocaine-induced Fos Activation 
  The effects of the M100907/MK212 cocktail on cocaine-induced Fos activation in 
striatal subregions are shown in Figure 14. Fos data are from the same animals whose 
behavioral data are shown in Figure 12. The ANOVA of percent control of Fos-positive 
nuclei in the dorsal CPu (Panel a) showed a significant between-group effect 
[F(4,30)=3.859, p<0.05]. Post-hoc comparisons showed significant differences between 
the saline + saline and saline + cocaine (p<0.05, Tukey HSD) groups, indicating that 
cocaine increased Fos expression in this region. There were also significant differences 
between saline + saline and MK212 + cocaine (p<0.05, Tukey HSD) and saline + saline 
and M100907 + cocaine (p<0.05, Tukey HSD) groups, suggesting neither drug alone 
reversed the effect of cocaine on Fos expression. In contrast, there was no significant 
difference between the saline + saline and cocktail + cocaine groups, indicating that the 
cocktail significantly attenuated cocaine-induced Fos expression. ANOVAs of percent 
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control of Fos-positive nuclei in the NAc core (Panel b) and shell (Panel c) and the 
infralimbic (Panel d) and prelimbic (Panel e) PFC failed to reveal any between-group 
effects. 
Discussion 
Results from the present study support our hypothesis that 5-HT2A and 5-HT2CRs 
interact to decrease cocaine-induced locomotor activity and Fos expression. We 
determined from dose-response experiments that the doses of 0.025 mg/kg M100907 and 
0.125 mg/kg MK212 had no effect on cocaine hyperlocomotion when given alone but 
these doses given in combination significantly attenuated cocaine hyperlocomotion, 
consistent with receptor interaction effects. The interaction effect was specific for cocaine 
hyperlocomotion as this dose combination had no effect on spontaneous locomotor 
activity. This dose combination also region-specifically attenuated cocaine-induced Fos 
expression in the dorsolateral CPu. It is likely that the effects of M100907 and MK212 
observed in the present study were in fact due to actions at 5-HT2A and 5-HT2C receptors, 
respectively. M100907 has >1000-fold selectivity for 5-HT2A vs. 5-HT2C receptors 
(Kehne, et al., 1996) and several studies have demonstrated that doses of 0.005-0.4 mg/kg 
reverse the behavioral effects of 5-HT2A agonists, but not those of 5-HT2CR agonists 
(Dekeyne, et al., 1999; Gresch, et al., 2007; Hitchcock, et al., 1997; McCreary, et al., 
2003; Vickers, et al., 2001; Wettstein, et al., 1999). MK212 binds to 5-HT2CRs with the 
highest affinity compared to other receptors, but it does have affinity for 5-HT2A, 5-HT2B 
and 5-HT3Rs (Cussac, Newman-Tancredi, Duqueyroix, Pasteau, & Millan, 2002; 
Glennon et al., 1989; Porter et al., 1999). It is unlikely that 5-HT2B receptors were 
involved in the effects observed in this study since previous research has found that 
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neither 5-HT2BR agonists nor antagonists have any effect on cocaine hyperlocomotion 
(Filip, Bubar, & Cunningham, 2004). Further, we have shown that the locomotor activity 
effects of even higher doses of MK212 (0.32-1.0 mg/kg), which should be less selective 
for 5-HT2CRs than the low doses used in the present study, are reversed by a selective 5-
HT2CR antagonist, SB242084 (Neisewander & Acosta, 2007; Pentkowski, et al., 2009; 
Pentkowski, et al., 2010).  The hypolocomotive effects of MK212 itself are also reversed 
by SB242084 (Stiedl et al., 2007). Thus it is likely that the low dose effects observed here 
are 5-HT2CR-mediated. 
Our findings fit with the existing literature, which clearly shows that both 5-
HT2AR antagonists and 5-HT2CR agonists given alone decrease cocaine hyperlocomotion, 
as well as reinstatement of cocaine-seeking behavior (Grottick, Fletcher, & Higgins, 
2000; McMahon, et al., 2001; Neisewander & Acosta, 2007; Nic Dhonnchadha, et al., 
2009; Pentkowski, et al., 2010; Pockros, et al., 2011). Similar results have been found in 
the nicotine literature as well, with 5-HT2AR antagonists decreasing nicotine self-
administration (Fletcher et al., 2012; Levin et al., 2008) and 5-HT2CR agonists attenuating 
nicotine self-administration as well as nicotine-induced locomotion, sensitization, 
conditioned place preference, and discriminative stimulus effects (Fletcher, et al., 2012; 
Grottick, Corrigall, & Higgins, 2001; Zaniewska, McCreary, Przegalinski, & Filip, 2007). 
5-HT2AR antagonists and 5-HT2CR agonists have also been shown to attenuate premature 
responding on a five-choice serial reaction time test with and without cocaine, suggesting 
a role in drug-induced impulsivity (Fletcher, Tampakeras, Sinyard, & Higgins, 2007). 
While there is ample evidence that 5-HT2A antagonists and 5-HT2C agonists have 
	   	   	  
51 
opposing effects, to our knowledge the present study is the first to demonstrate an 
interaction between these two serotonin receptor subtypes. 
Interestingly, the middle dose (0.05 mg/kg) of M100907 appeared to have a 
stronger effect than the highest dose (0.1 mg/kg). Previous research has shown that a 
higher dose of 0.5 mg/kg attenuates cocaine hyperlocomotion (Fletcher, et al., 2002), 
suggesting that there may be an inverted U-shaped dose-effect function for M100907 
effects on this behavior. The dose-effect function of M100907 on methamphetamine 
hyperlocomotion is similar, with a higher dose producing less robust attenuation than an 
intermediate dose (Steed, Jones, & McCreary, 2011). Some studies have shown dose-
dependent effects of M100907 on impulsivity (Agnoli & Carli, 2012) and reinstatement 
of nicotine-seeking behavior (Fletcher, et al., 2012), whereas M100907 effects on cue-
primed reinstatement of cocaine-seeking behavior (Nic Dhonnchadha, et al., 2009) do not 
appear to vary dose-dependently. 
The effects of M100907 and MK212 on cocaine-induced Fos expression in the 
dorsolateral CPu mimicked the behavioral data, where low doses of M100907 and 
MK212 had no effect on cocaine-induced Fos expression when given alone, but produced 
a significant decrease when given in combination. Although this study did not include 
control groups for possible effects of M100907 or MK212 alone on Fos expression, it is 
unlikely that these drugs altered Fos expression on their own given previous findings. For 
instance, it has been shown that M100907 (0.2-0.8 mg/kg) has no significant effect on 
Fos activation in the CPu after saline pretreatment (Szucs, et al., 2005). The effects of 
MK212 on Fos expression have not been examined, although another 5-HT2CR agonist, 
RO-60-1057, fails to alter Fos expression in the CPu at doses (1-3 mg/kg) that attenuate 
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cocaine-primed reinstatement (Beyeler et al., 2010; Grottick, et al., 2000). Furthermore, 
studies have previously found that cocaine-induced Fos expression in the CPu is altered 
by 5-HT2R manipulations. For instance systemic injections of M100907 attenuate 
cocaine-induced Fos in the CPu (Szucs, et al., 2005), and our laboratory has found that 
intra-mPFC infusions of MK212 also attenuate cocaine-induced Fos in the CPu (Pockros, 
et al., 2011). Thus, it is unlikely that these drugs induce Fos expression on their own, but 
instead selectively attenuate cocaine-induced Fos expression, similar to their selective 
attenuation of cocaine-induced hyperlocomotion without producing any effect on 
spontaneous locomotion. 
It is surprising that cocaine hyperlocomotion was associated with increased Fos 
expression only in the CPu and not in the NAc or PFC because several previous studies 
have found that acute injection of cocaine produces hyperlocomotion and increases Fos 
protein expression in all of these regions (Graybiel, Moratalla, & Robertson, 1990; Szucs, 
et al., 2005; S. T. Young, Porrino, & Iadarola, 1991). However, cocaine-induced Fos 
expression in the striatum exhibits a rostral to caudal increasing gradient. For instance, 
Szucs et al. (2005) found no effects of cocaine on Fos expression in the anterior NAc 
core or shell at +1.7 mm from Bregma, consistent with the lack of cocaine-induced Fos 
expression in the present study at +1.6 mm from bregma. However, in contrast to Szucs 
et al. (2005) who found only a nonsignificant trend toward an effect of cocaine on Fos 
expression in the CPu at +1.7 mm from Bregma, we found that cocaine significantly 
increased Fos in the CPu at +1.6mm from Bregma. This difference may be due to 
different slicing angles or staining or counting techniques. It is possible that we may have 
observed cocaine-induced Fos expression if we had analyzed tissue from the caudal 
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regions of the NAc core and shell because Szucs et al. (2005) only found significant 
effects at a more caudal level (i.e., +1.0 mm from Bregma). Contrary to our results, 
several studies have shown that cocaine (2 mg/kg, i.v. or 25 mg/kg) increases Fos 
expression in the medial PFC (Graybiel, et al., 1990; Kufahl, Pentkowski, Heintzelman, 
& Neisewander, 2009). However, differences in cocaine dose or different routes of 
administration may account for differences across studies. 
The similar pattern of changes in locomotion and Fos expression in the CPu 
suggests that this region is involved in the observed behavioral changes. Although, site-
specific injections will be necessary to determine the brain regions and cellular 
mechanisms involved in the functional receptor interaction, the CPu is likely involved 
given its role in stimulant-induced motor activities, including locomotion, repetitive 
stereotypic and habitual behaviors (Brown, et al., 1992; Naylor & Olley, 1972; White, et 
al., 1998; Zimmerberg & Glick, 1974). The dose of cocaine used in the present study (15 
mg/kg, i.p.) does not typically produce stereotypic behaviors, however slightly higher 
doses (20 mg/kg, i.p.) have been found to produce stereotopies typically manifesting as 
headbobbing (Bhattacharyya & Pradhan, 1979; Budygin, 2007; O'Dell, Khroyan, & 
Neisewander, 1996; White, et al., 1998). Repetitive stereotypic behaviors may compete 
with expression of cocaine hyperlocomotion; however, if stereotypy occurred in this 
study, the drugs co-administered with cocaine would likely have attenuated rather than 
exacerbated this behavior. Indeed 5-HT2AR antagonists, including M100907, have been 
found to attenuate stereotopy produced by other drugs (Barwick, Jones, Richter, Hicks, & 
Young, 2000; Higgins, Enderlin, Haman, & Fletcher, 2003; Ninan & Kulkarni, 1998). 
Similarly, 5-HT2CR mutant mice exhibit enhanced DAT antagonist-induced stereotypic 
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behavior (Abdallah et al., 2009), suggesting that stimulation of these receptors inhibits 
dopamine-induced stereotypy. Thus, it is unlikely that the reduction of cocaine 
hyperlocomotion was due to competing stereotypic behavior. 
Although the cellular mechanisms by which M100907 and MK212 produced their 
combined effect on cocaine hyperlocomotion and Fos expression remain to be elucidated, 
one possibility is via a decrease in DA release in the nigrostriatal pathway. Acute 
injection of cocaine has been shown to stimulate Fos expression (Neisewander, et al., 
2000; Zahm, et al., 2010) and increase DA in the CPu (Hurd & Ungerstedt, 1989; Hurd, 
Weiss, Koob, & Ungerstedt, 1990). 5-HT2A and 5-HT2CRs have been found to regulate 
amphetamine- and morphine-induced DA release in the CPu in opposing manners; 5-
HT2AR blockade attenuates phasic DA release (De Deurwaerdere & Spampinato, 1999; 
Gobert & Millan, 1999; Ichikawa & Meltzer, 1995; Lucas & Spampinato, 2000; Porras, 
et al., 2002; Schmidt, et al., 1992), while 5-HT2CR activation decreases both tonic and 
phasic DA activity (Di Giovanni, et al., 1999; Di Matteo, et al., 2000; Gobert, et al., 
2000; Porras, et al., 2002). Cellular localization of 5-HT2A and 5-HT2CRs in the dorsal 
CPu has yet to be determined, although the majority of 5-HT2AR-labeled cells in this 
region contain parvalbumin, indicative of γ-Aminobutyric acid (GABA) interneurons 
(Bubser, Backstrom, Sanders-Bush, Roth, & Deutch, 2001). In the mesolimbic pathway, 
5-HT2A and 5-HT2CRs are expressed on both DA and GABA neurons in the VTA, and on 
GABA neurons in the NAc. In the SN pars compacta, 5-HT2CRs are found on 
GABAergic neurons and 5-HT2CR agonists stimulate GABA release in the SN (Eberle-
Wang, Mikeladze, Uryu, & Chesselet, 1997; Invernizzi et al., 2007). Intra-CPu 
administration of a 5-HT2CR inverse agonist increases DA release in the CPu, an effect 
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that can be reversed by concurrent administration of a 5-HT2CR agonist mCPP (1.0 
mg/kg, i.p.) (Alex, et al., 2005). Thus, the 5-HT2A and 5-HT2CR interactive effects on 
cocaine hyperlocomotion and Fos expression in the CPu may be due to direct modulation 
of DA release from nigrostriatal neurons, or indirect modulation of DA release via an 
increase in GABA inhibition either within the dorsal CPu itself or within the SN. While 
we did not observe effects of M100907 and/or MK212 on Fos activation in the terminal 
regions of the mesocorticolimbic dopamine pathway, this does not rule out the possibility 
that this pathway is involved in the interaction effects.  
  We chose to test our hypothesis by examining effects of subthreshold doses of 
M100907 and MK212 on cocaine-induced locomotion to establish proof or principle that 
5-HT2A and 5-HT2CRs interact. Although this method of combining subthreshold doses is 
an approach that has been used to detect synergistic interactions (Brown, Finlay, Wong, 
Damsma, & Fibiger, 1991; Gotoh et al., 2006; Thiel, Sanabria, & Neisewander, 2009), 
there are some limitations. First, although statistically our findings are consistent with a 
synergistic interaction, the non-significant tendency of both drugs to attenuate cocaine 
hyperlocomotion when given alone raises the possibility that their interactive effect may 
be additive rather than synergistic. Thus, more sophisticated isobolographic analyses will 
be needed to precisely determine the nature of the 5-HT2A and 5-HT2CR interaction.  
Second, it remains unclear whether pharmacokinetic interactions between these drugs are 
involved in the interaction effect observed.  Future research will be needed to address 
these issues. 
In conclusion, the findings from this study provide support for the idea that a 
combination of 5-HT2A antagonist and 5-HT2C agonist may offer potential therapeutic 
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advantages for development of treatment for cocaine dependence. For instance, relatively 
low doses of two drugs could be used instead of a high dose of a single drug. These lower 
doses would likely be less disruptive than a high dose to various systems throughout the 
body involving these receptors, resulting in fewer side-effects. In support of this idea, the 
present findings indicate that combined subthreshold doses that decreased cocaine 
hyperlocomotion without disturbing spontaneous locomotion. 5-HT2CR agonists with 
greater selectivity have recently been developed that may improve upon therapeutic 
efficacy and used at a lower dose range in combination with 5-HT2AR antagonists. 
Clinical trials are currently investigating the effectiveness of 5-HT2AR antagonists in 
treating depression and insomnia and 5-HT2CR agonists in treating obesity (NIH, 2010), 
supporting the potential clinical utility of these drugs for treating addiction. Ideally, 
pharmacological treatments aimed at cocaine dependence should not only curtail the 
reinforcing effects of cocaine, but also drug craving and relapse (Washton, 1988). To 
further explore the potential clinical utility of a combination treatment with a 5-HT2AR 
antagonist and a 5-HT2CR agonist, future research is needed to determine whether the 
combination would reduce cocaine self-administration and drug-seeking behavior while 
not interfering with unconditioned behaviors (i.e. locomotion and feeding). 
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Chapter 4 
Effects of a 5-HT2CR agonist in the amygdala on reinstatement of cocaine-seeking 
behavior and anxiety on the elevated plus maze 
Increasing or decreasing 5-HT levels in the brain has been found to attenuate 
craving and cocaine-seeking behavior in humans (Aronson, et al., 1995; Batki, et al., 
1993; Satel, et al., 1995; Walsh, et al., 1994) and animals (Baker, et al., 2001; 
Burmeister, Lungren, & Neisewander, 2003; Tran-Nguyen, et al., 1999), respectively. 
This paradoxical relationship is thought to be due to activation of different 5-HT 
receptors in the brain that are involved in addiction, including the 5-HT2C receptor (R). 5-
HT2CR agonists attenuate cue- and cocaine-primed reinstatement of cocaine-seeking 
behavior, (Fletcher, et al., 2008; Neisewander & Acosta, 2007; Pentkowski, et al., 2010) 
while 5-HT2CR antagonists enhance cocaine hyperlocomotion as well as cocaine-primed 
reinstatement and cocaine self-administration (Fletcher, et al., 2002; McMahon, et al., 
2001).  
 5-HT2CRs are found throughout the mesolimbic DA pathway (Doherty & Pickel, 
2000; Pompeiano, et al., 1994), including the amygdala, which is a key region in the 
neurocircuitry of cocaine addiction (Alleweireldt, et al., 2006; O'Dell, et al., 1999; See, 
2005). Generally, the amygdala is involved in emotional learning (Bechara, et al., 1995) 
and memory (Cahill, 2000), fear conditioning (Blanchard & Blanchard, 1972; M. Davis, 
2000; Lieblich, Yitzhaky, & Cohen, 1976; Pribram, et al., 1979), avoidance learning 
(Weiskrantz, 1956), and appetitive conditioning (B. J. Everitt, Cardinal, Parkinson, & 
Robbins, 2003; Parkinson, Robbins, & Everitt, 2000).  The role of the amygdala in 
emotional conditioning and memory using natural reinforcers led researchers to 
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investigate involvement of the amygdala in drug abuse (B. J. C. Everitt, R. N.; Hall, J.; 
Parkinson, J. A.; Robbins, T. W., 2000; Grant, et al., 1996). 
The amygdala is a heterogenous region composed of subnuclei, including the 
basolateral and central amygdaloid nuclei (i.e., BlA and CeA respectively, (Gloor, 1955; 
Wood, Schottelius, Frost, & Baldwin, 1958). The BlA is responsible for assigning 
incentive value to a conditioned stimulus (CS) based on its association with an 
unconditioned stimulus (US, (B. J. C. Everitt, R. N.; Hall, J.; Parkinson, J. A.; Robbins, 
T. W., 2000), as well as for processing fear and anxiety (M. Davis, 2000; Sananes & 
Davis, 1992). For instance, the BlA has been implicated in processing the incentive 
motivational effects of drug-associated contextual and discrete cues (B. J. Everitt, et al., 
1999; Fuchs & See, 2002; Fuchs, et al., 2002; McLaughlin & See, 2003). 5-HT2CRs are 
found throughout the amygdala, with higher levels in the BlA than CeA (Clemett, 
Punhani, Duxon, Blackburn, & Fone, 2000; Lopez-Gimenez, et al., 1997; Pompeiano, et 
al., 1994). Although it is presently unclear whether 5-HT2CRs in the BlA play a role in 
processing the significance of cocaine-associated cues, they are involved in anxiety-like 
behavior. Transgenic mice overexpressing 5-HT2CR mRNA show enhanced anxiety on 
the elevated plus maze (EPM, (Kimura, et al., 2009), while 5-HT2CR knockout mice 
exhibit a reduction in anxiety on the EPM (Heisler, Zhou, et al., 2007). Systemic 
pretreatment with a 5-HT2CR agonist induces learned helplessness behaviors (Strong, et 
al., 2009), and 5-HT2CR agonists infused into the BlA potentiate anxiety-like behavior in 
open-field and social exploration tests (Campbell & Merchant, 2003; Christianson et al., 
2010). Further, the anxiogenic effects of a 5-HT2CR agonist can be reversed by intra-BlA 
infusion of a 5-HT2CR antagonist (de Mello Cruz et al., 2005). 
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The CeA is a part of the extended amygdala (Alheid & Heimer, 1988; Heimer & 
Alheid, 1991; Johnston, 1923), which is implicated in some of the unconditioned effects 
of drugs of abuse, including reward (O'Dell, et al., 1999), reinforcement (Caine, 
Heinrichs, Coffin, & Koob, 1995), stress, and drug withdrawal (Koob & Le Moal, 2005; 
Koob & Nestler, 1997). Inactivation of the CeA eliminates stress-primed reinstatement in 
both CPP (Ma, Xu, Yang, & Yang, 2008; Wang, Luo, Ge, Fu, & Han, 2002) and self-
administration models (McFarland, et al., 2004). Some studies suggest a role for the CeA 
in responding for cocaine-paired cues (Kruzich & See, 2001; Thiel et al., 2010), though 
selective inactivation of the CeA does not affect acquisition of (Kruzich & See, 2001), or 
responding with (Burns, Annett, Kelley, Everitt, & Robbins, 1996; Robledo, Robbins, & 
Everitt, 1996), conditioned reinforcement. The CeA appears to amplify conditioned 
responses, including the “incubation effect” in which cue-primed reinstatement 
intensifies during abstinence (Grimm & See, 2000; Y. Q. Li et al., 2008; Lu et al., 2005; 
Tran-Nguyen et al., 1998). Although the distribution of 5-HT2CRs in the CeA is not well 
characterized, it has been shown that 5-HT2CR knockout mice exhibit lower levels of Fos 
activation in the CeA following social-defeat stress (Heisler, Zhou, et al., 2007) and that 
5-HT2CR agonists increase Fos expression in the CeA (Singewald, Salchner, & Sharp, 
2003; Somerville, Horwood, Lee, Kennett, & Clifton, 2007). Further, there is a positive 
correlation between 5-HT2CR levels in the CeA and anxiety-like behavior on the EPM (Q. 
Li, Luo, Jiang, & Wang, 2012); however, other studies failed to find effects of 5-HT2CR 
agonists in the CeA on anxiety-like behavior (Campbell & Merchant, 2003; Christianson, 
et al., 2010). 
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In the present study, we hypothesized that 5-HT2CRs in the BlA play a role in the 
inhibitory effects of systemic 5-HT2CR agonists on cue reinstatement of extinguished 
cocaine-seeking behavior based on the known involvement of the BlA in the incentive 
motivational effects of cocaine-paired cues and the presence of 5-HT2CR in the BlA. We 
further hypothesized that 5-HT2CRs in the CeA play a role in the inhibitory effects of 
systemic 5-HT2CR agonists on cocaine-primed reinstatement based on the known 
involvement of the CeA in unconditioned effects of cocaine. To examine this hypothesis, 
we used the selective 5-HT2CR agonist, CP890101. This agonist has >500-fold selectivity 
for 5-HT2C over other 5-HT2Rs and EC50 values of 0.11, 153, and 65.3 nM for 5-HT2C, 
5-HT2A, and 5-HT2BRs, respectively (Fletcher et al., 2009; Siuciak et al., 2007). We 
predicted that CP809101 microinfused into the BlA would attenuate cue-primed 
reinstatement of cocaine-seeking behavior and increase anxiety-like behavior on the 
elevated plus maze (EPM), while having no effect on cocaine-primed reinstatement or 
extinction responding. Conversely, we predict that CP809101 infused into the CeA would 
attenuate cocaine-primed reinstatement of cocaine-seeking behavior, and may affect cue-
primed reinstatement or anxiety-like behavior on the EPM.  
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Methods 
Animals  
Adult male Sprague–Dawley rats weighing 275–325 g at the start of the 
experiments were used in this study. Animals were housed in a climate-controlled colony 
room with a 14-h reversed light/dark cycle (lights off at 7:00 a.m.) and cared for in 
accordance with the “Guide for the Care and Use of Laboratory Animals” (Institute of 
Laboratory Animal Resources on Life Sciences, National Research Council 2011).  
Surgery  
Animals were handled daily for at least 6 days before implanting catheters into 
the right jugular vein. Catheters were implanted using the same protocol as Pockros et al., 
2011. Stainless steel guide cannulae were lowered through small holes drilled into the 
skull to a depth 2.5 mm above the targeted site of the BlA and 2.7 mm above the targeted 
site of the CeA. The coordinates were selected based on previous research (Christianson, 
et al., 2010; Fuchs & See, 2002; Thiel, et al., 2010) as well as our own pilot surgeries, 
and were as follows: for the BlA the AP=-2.5, the ML= 5.0 mm to the left and 4.9 mm to 
the right relative to bregma, and the DV=-8.2 mm from the skull surface; for the CeA the 
AP=-2.5, the ML= 4.2 mm to the left and 4.1 mm to the right relative to bregma, and the 
DV=-8.2 mm from the skull surface (Paxinos, 2007). The guide cannulae and the metal 
end of the catheter were secured to the skull using dental acrylic cement and anchor 
screws. Metal stylets were inserted into the cannulae to maintain patency. All incisions 
were sutured and treated with a topical antibiotic. Catheters were flushed daily with a 
solution of 0.1 ml saline containing heparin sodium (70 U/ml; APP Pharmaceuticals, 
Schaumburg, IL, USA) and Timentin (66.7 mg/ml; GlaxoSmithKline, Research Triangle 
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Park, NC, USA) for 5 days after surgery and throughout the rest of self-administration 
training and testing. Animals were given at least 7 days of recovery from surgery before 
beginning self-administration training. Catheter patency was tested periodically by 
administering 0.05 ml Brevital (16.6 mg/ml, Jones Pharma Inc., St. Louis, MO, USA), 
which briefly anesthetizes the animal only if delivered i.v. 
Intracranial drug infusions 
 CP809101 (Tocris, Ellisville, MI, USA) was dissolved in artificial cerebral spinal 
fluid (aCSF). Microinjections were delivered over a 1-min period using a 30-gauge 
injector (Plastics One) connected via polyethylene 50 tubing (Becton Dickinson, Sparks, 
MD, USA) to a 25-µl syringe (Hamilton Co., Reno, NV, USA) housed in an infusion 
pump (CMA Microdialysis, North Chelmsford, MA, USA). Injection cannulae extended 
2.5 mm below the guide cannulae for the BlA and 2.7 mm below the guide cannulae for 
the CeA. Movement of an air bubble the proper distance through the drug infusion line 
confirmed successful infusion of the drug. After the infusion was complete, the injectors 
remained in place for 1 min to ensure thorough diffusion. After removing the injectors, 
metal stylets and caps were replaced before the animal was placed into the conditioning 
chamber for the test sessions. 
Self-administration 
 Cocaine self-administration training took place daily for 2 h, 6 days per week. 
Animals were trained in operant conditioning chambers (28 × 10 × 20 cm; Med 
Associates, St Albans, VT, USA), each containing an active lever, a cue light 4 cm above 
the active lever, an inactive lever, a tone generator (500 Hz, 10 dB above ground noise), 
and a house light on the wall opposite the levers. Upon pressing the active lever to 
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complete a schedule of reinforcement, the light and tone cues were simultaneously 
activated and followed 1 s later by a 0.1-ml cocaine (0.75 mg/kg, i.v.) infusion delivered 
over 6 s. The house light was then activated for a 20-s timeout period, during which 
active lever presses were recorded but had no effects. Responses on the inactive lever 
were recorded but had no effects. 
 For the first 5 days of training, all animals began on a fixed ratio (FR) 1 schedule of 
reinforcement with the capability to progress to a variable ratio (VR) 3, and finally VR5 
schedule within a session. After ending the session on a VR5 schedule for five 
consecutive days, animals then began the next session on a VR3 schedule. Once animals 
began on a VR3 schedule and ended on a VR5 schedule, they began on a VR5 schedule 
for the rest of the sessions. All animals were starting on a VR5 schedule by day 14 and 
were on a VR5 schedule exclusively for at least the last 5 days of self-administration. All 
animals were restricted to 16 g of food to facilitate acquisition of self-administration (M. 
E. Carroll, et al., 1981) and remained food-restricted until they ended on a VR5 schedule 
for three consecutive sessions. Animals were then given food ad libitum for the rest of the 
experiment. 
Extinction phase 
Extinction training began once rats had completed at least 15 self-administration 
sessions and had received food ad libitum for at least the last 5 sessions. Extinction 
training occurred daily for 1 h/day. Rats were placed into the self-administration 
chambers as before and lever presses were recorded, but produced no consequences (i.e., 
no infusions or cues were presented). Catheters were connected to the infusion lines 
during extinction, as well as during all reinstatement tests, even though the infusion lines 
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were not connected to a syringe. Extinction sessions continued for 10–14 days and until 
there was an 80% reduction in active lever pressing from the animals’ highest response 
rate during extinction or to less than 20 active lever presses for three consecutive days.  
Experiments 
Upon meeting the extinction criterion, animals with BlA and CeA cannulae 
(experiments 1 and 2, respectively) underwent CP809101-primed reinstatement testing, 
cue-primed reinstatement testing, cocaine-primed reinstatement testing, and elevated plus 
maze (EPM) testing for the effects of CP809101 (0, 0.01, 0.1, or 1.0µg/0.2µg/side). 
Assignment to dosage groups was counterbalanced based on the amount of cocaine intake 
during self-administration, as this has been shown to affect reinstatement response rates 
(Baker, et al., 2001; Deroche, Le Moal, & Piazza, 1999). Animals received their assigned 
dose of agonist prior to each type of reinstatement test. In experiment 3, a new cohort of 
animals with CeA cannulae underwent CP809101-primed reinstatement testing for the 
effects of CP809101 (0.01µg/0.2µL/side) or SB242082 (0.1µg/0.2µL/side), cocaine-
primed reinstatement testing for the effects of CP809101 (0.01µg/0.2µL/side) or 
CP809101+SB242084 (0.01ug and 0.1µg/0.2µL/side, respectively), and a subset of 
animals underwent EPM testing for the effects of vehicle and CP809101 (0 and 
0.01µg/0.2µL/side). 
CP809101-primed reinstatement testing  
 Following extinction training, animals were assigned to one of three CP809101 
dose groups (0.01, 0.1, or 1.0 µg/side), counterbalanced based on the amount of cocaine 
intake during self-administration as this has been shown to affect reinstatement responses 
(Baker, et al., 2001; Deroche, et al., 1999). Animals underwent two tests for CP809101-
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primed reinstatement of extinguished cocaine-seeking behavior, receiving a vehicle 
microinjection prior to one test and their assigned dose of CP809101 prior to the other 
test, with the order of these pretreatments counterbalanced. Immediately after receiving 
their assigned microinjection, animals were given a 1 h extinction session where 
responding on either lever had no consequences. 
Cue-primed reinstatement testing 
 Animals underwent two tests for cue reinstatement of extinguished cocaine-seeking 
behavior, receiving a vehicle microinjection prior to one test and their assigned dose of 
CP809101 prior to the other test, with the order of these pretreatments counterbalanced. 
Animals were given a minimum of three extinction days between tests to allow extinction 
baseline rates to stabilize. If animals failed to meet the reinstatement criteria of doubling 
extinction baseline response rates and at least twenty responses on the active lever on 
either of the two test days, they were considered “nonreinstaters” and excluded from the 
analysis. Immediately after receiving their assigned microinjection, animals were tested 
for 1 h with the same stimulus complex as that paired with cocaine during training 
available response-contingently on an FR1 schedule; however, no cocaine was delivered 
during cue tests. The FR1 schedule was used in place of the VR5 training schedule 
because we have previously shown that under tests for cue reinstatement the FR1 
schedule yields higher response rates, and thus greater sensitivity for detecting the 
predicted decrease, than the training schedule (Acosta, et al., 2008). A noncontingent cue 
presentation was delivered if the animal did not receive a response-contingent cue within 
the first 5 min of the session to minimize the possibility that animals would fail to press 
the lever leaving them unaware that cues were available. 
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Cocaine-primed reinstatement testing 
 After the two cue reinstatement tests, animals received at least three extinction 
sessions to re-establish a stable baseline extinction rate of responding. They were then 
given two tests for cocaine-primed reinstatement of extinguished cocaine-seeking 
behavior. Prior to one test, they received the same dose of CP809101 as they had 
received during cue reinstatement testing. For the other test, they received a vehicle 
microinjection. The order of the two pretreatments was counterbalanced within a group. 
Immediately after the microinjection, animals received a priming injection of cocaine (10 
mg/kg) and were then immediately placed into the conditioning chamber. Lever presses 
were recorded, but produced no consequences (i.e., no cues or cocaine were delivered). 
To control for injection stress, animals were given mock i.p. injections immediately 
before the extinction session preceding each of their cocaine-reinstatement tests and the 
average response rates during these sessions was used as the extinction baseline. Animals 
were given a minimum of three extinction sessions between tests to allow extinction 
baseline rates to stabilize. If animals failed to meet the reinstatement criteria of doubling 
baseline and at least twenty responses on the active lever during at least one of the 
reinstatement tests, they were considered “nonreinstaters” and were excluded from the 
analysis. 
Elevated plus maze testing 
 Following the completion of reinstatement testing, animals were tested for the 
effects of CP809101 on anxiety-like behavior on the EPM following at least a 5-day 
washout period from their last CP809101 treatment. Animals all received one test on the 
EPM and were assigned to receive the same dose of CP809101 from reinstatement testing 
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or vehicle. The EPM apparatus consisted of four Plexiglas arms arranged in a cross, 
elevated 75 cm above the floor. Each arm was 10 cm wide and 50 cm long, and each arm 
was joined at the center by a 10 cm square platform. The two opposite ‘open’ arms 
contained no walls, while the other two ‘closed’ arms had 40 cm high sides. Animals 
received their assigned microinjection 5-minutes prior to testing, and then were 
individually placed in the center of the apparatus facing one of the two closed arms (File, 
Lippa, Beer, & Lippa, 2004). The 10-min test was conducted under dim lighting, and 
behaviors were scored using Observer 5.0 software (Noldus Information Technology BV, 
Wageningen, The Netherlands) from videotapes by a highly trained observer blind to 
group assignment. The following behaviors were scored: total time spent in open arms, 
closed arms, and the middle of the maze; and total number of entries into open arms, 
closed arms, and the middle of the maze. Locomotor activity was also recorded and 
analyzed with a computer-automated video tracking system (Clever Systems, Reston, 
VA). The apparatus was cleaned with 0.05% ethanol between each test. 
Histology 
Animals were deeply anesthetized with 3% isoflurane and given intracranial 
infusions (0.2 µl/side) of 1% methylene blue to verify cannulae placements. Animals 
were then decapitated, brains were removed, frozen, and stored at -20°C.  Brains were 
later sliced in coronal sections (40 µm), stained with cresyl violet, and examined under a 
microscope by observers unaware of group assignment who determined the point of drug 
infusion. Animals with incorrect placement of the drug infusions were excluded from the 
analyses. A schematic of accurate cannulae placements is shown in Figure 15.  
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Statistical Analyses 
For self-administration/reinstatement, data were analyzed using mixed-factor 
analyses of variance (ANOVAs) with session (e.g. extinction baseline, vehicle test, and 
CP809101 test) as a within-subjects factor and dosage group (0.01, 0.1 and 1.0 µg/0.2 
µl/side) as a between-subject factor. Effect size (η2) was also calculated for significant 
interactions. A Greenhouse-Geisser correction of degrees of freedom was used to correct 
for heterogeneity of variance in the data. Subsequent post-hoc comparisons were made 
using tests of simple main effects. In addition, planned t-tests were used to test the 
predictions that cocaine-seeking behavior would increase after cocaine priming or cue 
presentation relative to baseline. Baseline values were calculated as the average of the 
sessions that occurred before each test day (i.e., the day before testing with agonist and 
the day before testing with vehicle). 
For EPM testing, data were analyzed using one-way ANOVAs of percent of time 
spent on the open arms with dosage group as a between-subjects factor. In addition, 
planned t-tests were used to test the prediction that anxiety-like behavior would increase 
after CP809101 relative to vehicle pretreatment. We also calculated an anxiety index 
score described previously (Huynh, Krigbaum, Hanna, & Conrad, 2011) as follows: 
Anxiety Index = 1 – [(open arm time/10 min) + (open arm entry/10 min)] / 2 
Results 
Experiment 1 
Intra-BlA infusion effects on extinction  
Active and inactive lever presses during the first session of extinction training are 
shown in Table 3. All animals had at least 10 extinction sessions before reinstatement 
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testing began. The ANOVA of the number of active lever presses/h on the first day of 
extinction versus the last day of extinction before testing showed a main effect of day 
[F(1,19)=87.18, P<0.001] but no dose effect or interaction with dose. The main effect 
indicated a significant drop in responding across training sessions. There were no 
differences in inactive lever presses. 
Effects of CP809101 in the BlA on reinstatement of cocaine-seeking behavior 
Figure 16 illustrates that CP809101 priming injections infused into BlA prior to 
testing failed to alter responding relative to extinction baseline. The ANOVA of 
responses/h indicated that there were no significant effects on response rates on either the 
active or inactive levers. 
Effects of CP809101 in the BlA on cue reinstatement of cocaine-seeking behavior 
Figure 17 shows the effects of CP809101 infusions into the BlA on cue-elicited 
reinstatement of cocaine-seeking behavior. There was 1 rat out of 27 that failed to meet 
the reinstatement criteria and was excluded from the analyses. The ANOVA of 
responses/h on the active lever showed a main effect of test day [F(1.30,24.77)=20.51, 
P<0.001, η2=0.510] but no interaction with dose or main effect of dose. Tests of simple 
main effects indicated that when collapsed across dose, all animals showed cue 
reinstatement evident as an increase in responding on the vehicle and CP809101 
pretreatment test days relative to the extinction baseline (p<0.05). Table 3 shows inactive 
lever presses on CP809101 test days for all groups. There were no significant differences 
in inactive lever presses. 
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Effects of CP809101 in the BlA on cocaine-primed reinstatement of cocaine-seeking 
behavior 
 Figure 18 illustrates the effects of intra-BlA infusions of CP809101 on cocaine-
primed reinstatement of cocaine-seeking behavior. There were 4 animals out of 27 that 
failed to meet the reinstatement criteria and were excluded from the analyses. The 
ANOVA of responses/h on the active lever indicated a significant main effect of test day 
[F(1.45,24.71)=6.84, P<0.01, η2=0.276] but no interaction with dose or main effect of 
dose. Tests of simple main effects indicated that when collapsed across dose, all animals 
showed cocaine-primed reinstatement evident as an increase in responding on the vehicle 
and CP809101 pretreatment test days relative to the extinction baseline (p<0.05). There 
were no differences in inactive lever presses (see Table 3).   
Effects of CP809101 in the BlA on anxiety-like behavior on the elevated plus maze 
 Figure 19 shows the effects of CP809101 infused into the BlA on the percent of 
time spent on the open arms of the EPM. The ANOVA failed to show a significant effect 
of CP809101 dose, however planned comparisons indicated a significant difference 
between the vehicle and 1.0µg/µL groups (p<0.05). Figure 20 shows the effects of 
CP809101 infused into the BlA on an anxiety index score which accounts for percent of 
time spent in the open arms as well as number of open arm entries (Huynh, et al., 2011). 
The ANOVA did not show a significant effect of CP809101 dose, however planned 
comparisons indicated a marginally significant difference between the vehicle and 1.0 
µg/µL groups (p=0.052). 
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Effects of CP809101 in the BlA on locomotor activity 
 Figure 21 shows the effects of CP809101 infused into the BlA on spontaneous 
locomotor activity. The ANOVA of total distance traveled failed to show a significant 
effect of dose.  
Experiment 2 
Extinction behavior of animals with CeA cannulae 
Active and inactive lever presses during the first session of extinction training are 
shown in Table 3. All animals had at least 10 extinction sessions before reinstatement 
testing began. ANOVAs of the number of active and inactive lever presses/h on the first 
day of extinction versus the last day of extinction before testing showed significant main 
effects of day [F(1,20)=90.92, P<0.001 and F(1,20)=4.63, P<0.05, respectively] but no 
dose effect or interaction with dose. The main effects indicated a significant drop in 
responding across training sessions. 
Effects of CP809101 in the CeA on reinstatement of cocaine-seeking behavior 
Figure 22 illustrates that CP809101 priming injections infused into CeA prior to 
testing failed to alter responding relative to extinction baseline. The ANOVA of 
responses/h indicated that there were no significant effects on response rates on either the 
active or inactive levers. 
Effects of CP809101 in the CeA on cue reinstatement of cocaine-seeking behavior 
Figure 23 shows the effects of CP809101 infusions into the CeA on cue-elicited 
reinstatement of cocaine-seeking behavior. The ANOVA of responses/h on the active 
lever showed a significant main effect of test day [F(1.33,26.60)=23.78, P<0.001, 
η2=0.543] but no interaction with dose. There was a nonsignificant trend toward a main 
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effect of dose of CP809101 [F(2,20)=3.22, P=0.061, η2=0.244], however there were no 
statistical differences between CP809101 and vehicle test days at any specific dose. Tests 
of simple main effects indicated that when collapsed across dose, all animals showed cue 
reinstatement evident as an increase in responding on the vehicle and CP809101 
pretreatment test days relative to the extinction baseline (p<0.05). Table 3 shows inactive 
lever presses on CP809101 test days for all groups. There were no significant differences 
in inactive lever presses. 
Effects of CP809101 in the CeA on cocaine-primed reinstatement of cocaine-seeking 
behavior 
 Figure 24 illustrates the effects of intra-CeA infusions of CP809101 on cocaine-
primed reinstatement of cocaine-seeking behavior. There were 3 animals out of 23 that 
failed to meet the reinstatement criteria and were excluded from the analyses. The 
ANOVA of responses/h on the active lever indicated a significant day by dose interaction 
[F(4,34)=4.06, p<0.01, η2=0.323] as well as a main effect of test day [F(2,34)=12.33, 
P<0.001, η2=0.420]. Post hoc comparisons indicated an increase in responding relative to 
the extinction baseline on all vehicle test days and CP809101 test days at the 0.1 and 
1.0µg/µL doses (t-test, p<0.05) and a significant decrease in lever pressing at the 
0.01µg/µL dose of CP809101 compared to vehicle (t-test, p<0.05). Although the vehicle 
test days appear to have a fair amount of variance by dosage group, there were no 
significant differences between them. Further, there were no differences between animals 
that received their vehicle test day first compared to those that received their vehicle test 
day second. There were no differences in inactive lever presses (see Table 3).   
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Effects of CP809101 in the CeA on anxiety-like behavior on the elevated plus maze 
 Figure 25 shows the effects of CP809101 infused into CeA on the percent of time 
spent on the open arms of the EPM. The ANOVA failed to show a significant effect of 
CP809101 dose although planned comparisons indicated a trend toward a difference 
between the vehicle and 0.1µg/µL groups (p=0.071). Figure 26 shows that CP809101 
infused into the CeA had no effect on anxiety index score.  
Effects of CP809101 in the CeA on locomotor activity 
 Figure 27 shows the effects of CP809101 infused into CeA on spontaneous 
locomotor activity. The ANOVA of total distance traveled failed to show a significant 
between-group effect of dose.  
Experiment 3 
Extinction behavior of animals with CeA cannulae 
Active and inactive lever presses during the first session of extinction training are 
shown in Table 3. All animals had at least 10 extinction sessions before reinstatement 
testing began. ANOVAs of the number of active and inactive lever presses/h on the first 
day of extinction versus the last day of extinction before testing showed significant main 
effects of day [F(1,14)=82.99, P<0.001 and F(1,14)=10.26, P<0.01, respectively] but no 
dose effect or interaction with dose. The main effects indicated a significant drop in 
responding across training sessions. 
Effects of CP809101 and SB242084 in the CeA on reinstatement of cocaine-seeking 
behavior 
Figure 28 illustrates the effects of CP809101 or SB242084 priming infusions into 
CeA prior to testing on responding relative to extinction baseline. The ANOVA of 
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responses/h indicated that there were no significant effects on response rates on either the 
active or inactive levers. 
Effects of CP809101+SB242084 in the CeA on cocaine-primed reinstatement of 
cocaine-seeking behavior 
 Figure 29 illustrates the effects of intra-CeA infusions of CP809101 or 
CP809101+SB242084 on cocaine-primed reinstatement of cocaine-seeking behavior. 
There were 3 animals that failed to meet the reinstatement criteria and 1 animal that was 
an outlier (i.e., more than 2 standard deviations above the mean without data from the 
animal in question), and all 4 were excluded from the analyses. The ANOVA of 
responses/h on the active lever indicated a significant day by condition interaction 
[F(2,20)=9.30, p<0.01, η2=0.482] as well as a main effect of test day [F(2,20)=24.53, 
P<0.001, η2=0.710]. Post hoc comparisons indicated an increase in responding relative to 
the extinction baseline on all vehicle test days and on CP809101 or 
CP809101+SB242084 test days (t-test, p<0.05) as well as a significant decrease in lever 
pressing when animals received CP809101 compared to vehicle (t-test, p<0.01). There 
was a significant difference between vehicle test days for animals that received 
CP809101 compared to those that received CP809101+SB242084 (t-test, p<0.05). There 
were no differences in inactive lever presses (see Table 3).   
Discussion 
 Results from the present study partially support our hypothesis that 5-HT2CRs in 
the BlA are involved in cue-primed reinstatement and anxiety-like behavior, whereas 
those in the CeA are involved in cocaine-primed reinstatement. We found that the 5-
HT2CR agonist, CP809101, infused into the BlA increased anxiety-like behavior on the 
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EPM. This result is consistent with findings that intra-BlA infusions of 5-HT2CR 
agonists, including CP809101, increase anxiety-like behavior in other anxiety paradigms 
(Campbell & Merchant, 2003; Christianson, et al., 2010; Q. Li, et al., 2012). Intra-CeA 
infusions of CP809101 also consistently attenuated cocaine-primed reinstatement at the 
lowest dose, and this effect was reversed with co-administration of a 5-HT2CR antagonist. 
CP809101 in the BlA or CeA had no effect on locomotor activity, so the anxiogenic 
effects in the BlA were likely not great enough to produce freezing behavior nor were the 
decreases in cocaine-seeking behavior likely due to nonspecific effects on motor 
function. 
Surprisingly, we found no support for our hypothesis that actions at 5-HT2CRs via 
CP809101 in the BlA attenuate cue-primed reinstatement. This hypothesis was based on 
previous findings demonstrating a role of the BlA in cue-primed reinstatement (B. J. 
Everitt, et al., 1999; Fuchs & See, 2002), an abundance of 5-HT2CRs in this region 
(Clemett, et al., 2000), and consistent attenuation of cue-primed reinstatement by 5-
HT2CR agonists (Burbassi & Cervo, 2008; Higgins & Fletcher, 2003; Neisewander & 
Acosta, 2007; Pentkowski, et al., 2010). It is possible that the doses of CP809101 tested 
were outside the range of effective doses for cue-primed reinstatement, however we 
observed significant effects at both the lowest and highest doses on other behavioral tests, 
which mitigates this explanation. Since the highest dose of CP809101 in the BlA 
increased anxiety-like behavior on the EPM and moderate acute anxiety increases cue-
primed reinstatement (Feltenstein, Henderson, & See, 2011), it is possible that there were 
opposing effects of cue incentive motivation on cocaine-seeking behavior and stress-
induced attenuation of behavior, resulting in a null effect. 
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 Interestingly, the effects of CP809101 in the CeA on cocaine-primed 
reinstatement were only seen at the lowest dose. It is not uncommon to observe a U-
shaped dose-response effect where only intermediate doses are effective (J. M. S. Davis, 
D. J., 1990; Neisewander, O'Dell, & Redmond, 1995). It is likely that as the dose of 
CP809101 decreases lower than the effective dose of 0.01 µg/µL/side in the CeA, the 
effects on cocaine-primed reinstatement diminish, resulting in an inverted U-shaped 
dose-response function. Unfortunately, we may not have captured the full CP809101 
dose-response function in this study, however our results as well as Christianson et al. 
(2010) found that 1.0 µg/µL/side in the BlA effectively increased anxiety-like behavior 
while 0.01 µg/µL/side was ineffective. One explanation for the lack of effect at higher 
doses is that these doses may produce nonspecific effects at 5-HT2ARs, which would have 
an opposite effect on cocaine-primed reinstatement from 5-HT2CR agonist inhibition 
effect (Fletcher, et al., 2002; Nic Dhonnchadha, et al., 2009). CP809101 is highly 
selective for 5-HT2CRs over 5-HT2A and 5-HT2BRs (Barnes & Sharp, 1999; Fletcher, 
Sinyard, & Higgins, 2010; Fletcher, et al., 2009; Siuciak, et al., 2007), however with 
administration directly into the brain it is possible that the higher doses in this study were 
high enough to activate 5-HT2ARs. Further, as the CeA is not densely packed with 5-
HT2CRs, the ratio of 5-HT2CR:5-HT2AR occupancy may be lower than in other regions 
with higher levels of 5-HT2CRs, such as the BlA (Clemett, et al., 2000; Q. Li, et al., 
2012). 5-HT2AR antagonists have been found to produce anxiogenic effects (Graeff, 
Guimaraes, De Andrade, & Deakin, 1996; Graeff, Netto, & Zangrossi, 1998), so this may 
be responsible for the trend toward an intra-CeA CP809101 effect on the EPM as well. In 
any case, the effect of the lowest dose of CP809101 in the CeA on cocaine-primed 
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reinstatement was replicated and reversed with co-administration of a 5-HT2CR 
antagonist, providing strong evidence that this is a 5-HT2CR-mediated effect.  
 There was an unusual amount of variability in our vehicle test results for cocaine-
primed reinstatement with infusions into the CeA. When CP809101 was injected into the 
CeA in experiment 2, the lowest dose consistently attenuated cocaine-primed 
reinstatement but we observed unusually high responding on the vehicle test day for this 
group. Statistically, however, there were no significant differences in vehicle test days 
across the dose groups, nor was there an order effect between animals that had their 
vehicle test first compared to second. In experiment 3, we again found a significant 
difference between vehicle and CP809101, as well as vehicle and SB242084, groups. 
Furthermore, there was again no order effect between animals that had their vehicle test 
first compared to second. The lack of order effects is likely due to the fact that there is a 
high amount of variability in lever pressing and the n=2-4 when split by drug and testing 
order, which reduces power to detect a potential order effect.  Thus we speculate that 
order of drug versus vehicle contributes to the high variance. Specifically, when the low 
dose of CP809101 was tested before vehicle, the suppression of cocaine-primed 
reinstatement may have resulted in a higher amount of lever pressing on the subsequent 
vehicle reinstatement test. By contrast, when the highest dose of CP809101 was tested 
first in experiment 2, there was no suppression of responding so extinction learning 
during that test likely resulted in lower responding on the subsequent vehicle test. While 
the variance in responding on vehicle test days in experiments 2 and 3 is curious, it does 
not detract from the reliability of our findings that 0.01 µg/0.2µL CP809101 in the CeA 
attenuated cocaine-primed reinstatement. 
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Other issues that are important to consider when using intracranial drug 
administration are spread of the drug to neighboring regions and potential damage or 
tolerance from repeated drug infusions. Because the BlA and CeA border each other, the 
region specificity of the effects suggests that the drug effects are not due to spread to a 
neighboring region. Animals underwent EPM testing at the end of the experiment when 
they had already received two to three injections of CP809101, and we still observed a 
significant effect of CP809101 in the BlA on this test. This finding mitigates the idea that 
tolerance to CP809101 developed or that there was a nonspecific effect of repeated 
infusion. Further, histological verification of cannula placements showed no evidence of 
excessive tissue damage from repeated infusions.  
We targeted the rostral section of the BlA. The rostral (rBlA) and caudal (cBlA) 
subsections of the BlA have divergent projections to the NAc core and dorsal agranular 
insular PFC, and NAc shell and prelimbic PFC, respectively (Groenewegen, Berendse, 
Wolters, & Lohman, 1990; Kita & Kitai, 1990; Shinonaga, Takada, & Mizuno, 1994). 
Inactivation of the rBlA using excitotoxic lesions, tetrodotoxin (TTX), and lidocaine 
inactivation has been consistently shown to disrupt cue-primed reinstatement (Grimm & 
See, 2000; Kantak, Black, Valencia, Green-Jordan, & Eichenbaum, 2002; Meil & See, 
1997), while cBlA lidocaine inactivation reduces drug-seeking behavior during cocaine 
self-administration (Kantak, et al., 2002). Other studies have found effects of 
pharmacological manipulations in the cBlA on both cue- and cocaine-primed 
reinstatement (Alleweireldt, et al., 2006; Berglind, Case, Parker, Fuchs, & See, 2006), 
and in the rBlA on cue-primed reinstatement (Alleweireldt, et al., 2006; Mashhoon, 
Tsikitas, & Kantak, 2009). Thus, if 5-HT2CRs in the BlA are involved in cue-primed 
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reinstatement, we likely would have observed an effect of CP809101 as the injections 
were in the rBlA.  
Based on previous literature, we expected CP809101 in the BlA, but not the CeA 
to affect anxiety-like behavior. We did observe a non-significant increase in anxiety-like 
behavior from CP809101 in the CeA, though the previous literature on 5-HT2CRs in the 
CeA is inconsistent (Campbell & Merchant, 2003; Christianson, et al., 2010; Heisler, 
Zhou, et al., 2007; Q. Li, et al., 2012), so 5-HT2CRs in this region may play are less 
prominent role in anxiety than the BlA 5-HT2CRs. Accordingly, Campbell and Merchant 
(2003) found that a 5-HT2CR agonist, mCPP, in the CeA did not affect ultrasonic 
vocalizations or exploratory behavior on a novel-object task, though in the BlA it 
increased ultrasonic vocalizations and decreased exploratory behavior on a novel-object 
task, which is consistent with an anxiogenic effect. Similarly, Christianson et al. (2010) 
found that a 5-HT2CR antagonist, SB242084, in the CeA did not affect anxiety-like 
behavior on a juvenile social exploration task, though in the BlA the antagonist decreased 
anxiety-like behavior. The elevated plus maze is a well-accepted test of anxiety in rodents 
where animals spend more time in the two closed arms of the maze when anxious than in 
the two open arms. Time spent in the open arms is also correlated with higher levels of 
the stress hormone, CORT, and is thought to be a measure of anxiety-like behavior 
(Pellow, Chopin, File, & Briley, 1985). 5-HT activates the hypothalamic-pituitary-
adrenal (HPA) axis (Fuller & Snoddy, 1980), an effect that is thought to involve 5-HT2CR 
stimulation (Heisler et al., 2007). Findings from our study and others suggest that the BlA 
is likely involved in the anxiogenic behavioral effects of 5-HT2CR stimulation. 
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While we can only speculate about the neurocircuitry underlying the effects of 
CP809101 on anxiety-like behavior in the BlA and cocaine-primed reinstatement in the 
CeA, we hypothesize that the mechanism is via modulation of GABA release. In the BlA, 
5-HT2CRs activate GABA interneurons (Stein, Davidowa, & Albrecht, 2000), however it 
is hypothesized that this effect is overshadowed by activation of projection neurons at 
higher doses (Rainnie, 1999) and leads to the anxiogenic effects of 5-HT2CR agonists 
(Campbell & Merchant, 2003). It is also possible that 5-HT2CR-induced GABA activation 
may inhibit other GABA interneuron inhibition of projection neurons, thus resulting in 
net disinhibition and anxiety-like behavior. To our knowledge, the cellular localization of 
5-HT2CRs in the CeA is not known, however it is possible that they are located on GABA 
interneurons and thus 5-HT2CR agonists in this region would increase GABA inhibition. 
Accordingly, GABA receptor agonists in the CeA attenuate footshock-primed 
reinstatement of cocaine-seeking behavior (McFarland, et al., 2004). While we did not 
assess the effects of CP809101 on stress-primed reinstatement, the CeA is involved in 
both stress and primary reinforcing effects of cocaine (Cain, Denehy, & Bardo, 2008; 
McFarland, et al., 2004; O'Dell, et al., 1999). However, since we did not observe an 
anxiogenic effect of CP809101 in the CeA, involvement of 5-HT2CRs in the CeA in 
stress-primed reinstatement would likely be due to the motivational impact of the stressor 
rather than an anxiogenic effect. 
In conclusion, our results suggest that 5-HT2CR activation in the CeA reduces 
cocaine-primed reinstatement, an effect that was reversed with concurrent administration 
of a 5-HT2CR antagonist. We also found an anxiety-like effect with 5-HT2CR activation in 
the BlA, but no effect on cue-primed reinstatement. The lack of effects of CP809101 in 
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the BlA on cue-primed reinstatement was surprising and warrants additional 
investigation, perhaps with approaches that alter expression of 5-HT2CRs in this region to 
verify our findings. CP809101 in the CeA did not significantly affect anxiety-like 
behavior on the EPM, and CP809101 in either region of the amygdala had no effect on 
locomotor activity. From these data, we conclude that 5-HT2CRs in the BlA play a role in 
anxiety and 5-HT2CRs in the CeA mediate the incentive motivational effects of cocaine 
priming.  
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Chapter 5 
Concluding Remarks 
The purpose of this dissertation was to examine the role of 5-HT2Rs in brain 
regions involved in reward on cocaine abuse-related behaviors and to explore the use of 
5-HT2R drugs for the treatment of cocaine abuse and dependence. Specifically, Chapter 2 
investigated the effects of a 5-HT2AR antagonist localized to the mPFC on cocaine-
seeking behavior; Chapter 3 examined a combination of a 5-HT2AR antagonist and 5-
HT2CR agonist on cocaine hyperlocomotion and neuronal activation in the dorsal 
striatum; Chapter 4 examined the effects of a 5-HT2CR agonist localized to either the BlA 
or CeA on anxiety-like and cocaine-seeking behaviors. 
We hypothesized that a 5-HT2AR antagonist in the mPFC would attenuate the 
incentive motivational effects of cocaine and cocaine-paired cues based on previous 
findings that 5-HT in the mPFC plays a role in cocaine-seeking behavior (Pentkowski, et 
al., 2010), 5-HT2AR antagonists attenuate cocaine-seeking behavior when given 
systemically (Fletcher, et al., 2002; Nic Dhonnchadha, et al., 2009), and the PFC plays a 
role in impulsivity and decision-making (Bechara, et al., 1994; Damasio, et al., 1994; 
Puumala & Sirvio, 1998), which contribute to drug abuse (Capriles, et al., 2003; 
Childress, et al., 1999). We found that the selective 5-HT2AR antagonist, M100907, 
microinfused into the mPFC dose-dependently attenuated cue-primed reinstatement of 
cocaine-seeking behavior, consistent with its effects when given systemically (Nic 
Dhonnchadha, et al., 2009). Surprisingly, M100907 infusions in the mPFC had no effect 
on cocaine-primed reinstatement in contrast to its systemic effects (Fletcher, et al., 2002; 
Nic Dhonnchadha, et al., 2009). The effects of M100907 in the mPFC were specific to 
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cue-induced motivation for cocaine, as the drug failed to affect cue-primed reinstatement 
of sucrose-seeking behavior. This finding together with a lack of effect on spontaneous or 
cocaine-induced locomotion suggests that the decrease in cue reinstatement of cocaine-
seeking behavior is not due to locomotor activity deficits. Further, M100907 infused into 
a neighboring region of the cortex failed to affect cue-primed reinstatement, supporting 
the anatomical specificity of the effect in the mPFC.  
Our findings from this study and Pentkowski et al, 2010 support the role of the 
PFC in cocaine-seeking behavior. After extended drug use, addicts exhibit 
“hypofrontality,” or deficits in PFC activation, which is thought to contribute to their lack 
of control over continued drug use (Childress, et al., 1999; Goldstein & Volkow, 2002).  
Despite this reduction in baseline PFC functioning, when exposed to drug-associated 
cues, animals and humans with drug history actually exhibit increased activity in the 
PFC, likely due to activation of the mesocorticolimbic DA pathway (Childress, et al., 
1999; Ciccocioppo, et al., 2001; Grant, et al., 1996; Maas, et al., 1998; Neisewander, et 
al., 2000). While we have not determined the neuroanatomical pathways underlying the 
attenuation of cocaine-seeking behavior by 5-HT2AR antagonists and 5-HT2CR agonists, 
they likely involve inhibition of the mesocorticolimbic DA pathway via increases in 
GABA or decreases in glutamate in the mPFC to reduce excitatory outputs to the VTA 
and NAc (Di Ciano & Everitt, 2001; McFarland, et al., 2003). An important future 
direction is to examine the circuitry of these localized effects of a 5-HT2AR antagonist 
and 5-HT2CR agonist in the mPFC.  
In Chapter 3 we discovered an interaction between a 5-HT2AR antagonist and 5-
HT2CR agonist. 5-HT2AR antagonists and 5-HT2CR agonists have been investigated for 
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their treatment potential in several mental health disorders, including schizophrenia, 
obesity, and addiction (Barnes & Sharp, 1999; Sargent, et al., 1997). However, both have 
side effects including sleep and appetite disturbances (Morairty, Hedley, Flores, Martin, 
& Kilduff, 2008; Sargent, et al., 1997), which may reduce their effectiveness in a clinical 
setting. Ideally, we may be able to use lower doses of these ligands to avoid side effects, 
while still maintaining therapeutic effects. We hypothesized that concurrent 5-HT2AR 
antagonism and 5-HT2CR agonism using subthreshold doses may interact to reduce the 
effects of cocaine. Accordingly, we found that ineffective doses of M100907 and 
MK212, a 5-HT2CR agonist, attenuated cocaine hyperlocomotion and cocaine-induced 
Fos activation in the dorsal striatum only when given together. The reduction of Fos in 
the CPu is fitting as this region is highly involved in stimulant-induced locomotion, 
stereotypy, and habitual behaviors (Brown, et al., 1992; Naylor & Olley, 1972; White, et 
al., 1998; Zimmerberg & Glick, 1974). Similarly, another recent study found that a 
combination of subthreshold doses of M100907 and WAY163909, another 5-HT2CR 
agonist, attenuated cocaine hyperlocomotion, cocaine-induced impulsivity, and cue- and 
cocaine-primed reinstatement (Cunningham, et al., 2013). Further, M100907 and Ro60-
0175, another 5-HT2CR agonist, were shown to decrease Zif protein activation in the 
dorsal striatum (Burton, Rizos, Diwan, Nobrega, & Fletcher, 2013). The findings from 
these studies reinforce our conclusion that a 5-HT2AR antagonist and 5-HT2CR agonist 
interact and involve the dorsal striatum to attenuate cocaine-related behaviors.  
A future direction is to clarify the role of the CPu in the interaction between a 5-
HT2AR antagonist and 5-HT2CR agonist. This study suggests the nigrostriatal pathway 
rather than the mesolimbic pathway may be a point of 5-HT2AR and 5-HT2CR interaction 
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effects. We have conducted an unpublished follow-up study examining the effects of 
intra- CPu administration of M100907 and another 5-HT2CR agonist, CP809101, on 
cocaine hyperlocomotion, however this combination treatment had no effect on 
systemically administered cocaine (15 mg/kg, i.p.). However, we did find that systemic 
administration of M100907 and CP809101 attenuated intra-CPu administration of 
cocaine (100µg/0.5µL/side). These findings lead us to hypothesize that systemic 
administration of M100907 and CP809101 may attenuate DA release in the CPu via 5-
HT2AR blockade and 5-HT2CR activation in the substantia nigra pars compacta (SNpc). 
While we have not directly tested this hypothesis yet, 5-HT2A and 5-HT2CRs are found in 
the SNpc (Cornea-Hebert, et al., 1999; Lopez-Gimenez, et al., 1997; Pasqualetti et al., 
1999) and this region sends a rich DA projection to the CPu, so this is a plausible 
explanation. We plan to further test this idea by administering M100907 and CP809101 
directly into the SNpc to examine the effects on cocaine hyperlocomotion and Fos 
activation in the CPu. 
Another future direction to this study mentioned by Cunningham et al, 2013 is to 
develop a single ligand to act as a dual 5-HT2AR antagonist and 5-HT2CR agonist. Some 
studies suggest that this type of treatment may be ideal for using low doses, thus 
increasing compliance by reducing side effects (Kiessling, Gestwicki, & Strong, 2006; 
Zhou et al., 2006). This is an important avenue to explore for pharmacological treatment 
of addiction, however to our knowledge a dual 5-HT2AR antagonist and 5-HT2CR agonist 
has not yet been developed. 
Finally, the last set of experiments in Chapter 4 sought to localize the effects of a 
5-HT2CR agonist in the BlA and CeA. 5-HT2CR agonists attenuate cocaine-seeking 
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behavior (Fletcher, et al., 2008; Neisewander & Acosta, 2007; Pentkowski, et al., 2010), 
and also increase anxiety-like behavior when given systemically or directly into the BlA 
(Campbell & Merchant, 2003; Christianson, et al., 2010; Heisler, Pronchuk, et al., 2007). 
Since the BlA and CeA are highly involved in cue- and cocaine-primed reinstatement, 
respectively, and 5-HT2CRs are found in these regions, we hypothesized that localized 5-
HT2CR agonism in the BlA may attenuate cue-primed reinstatement and increase anxiety-
like behavior, while CP809101 in the CeA would attenuate cocaine-primed reinstatement. 
We found that CP809101 in the BlA increased anxiety-like behavior on the EPM, but had 
no effect on cue- or cocaine-primed reinstatement. CP809101 in the CeA attenuated 
cocaine-primed reinstatement, and this effect was reversed with concurrent 
administration of a 5-HT2CR antagonist, but had no effect on cue-primed reinstatement or 
anxiety-like behavior on the EPM. We were surprised that CP809101 in the BlA did not 
attenuate cue-primed reinstatement due to the important role of the BlA in cue-primed 
reinstatement (B. J. Everitt, et al., 1999; Fuchs, et al., 2002) and the consistent attenuation 
of cue-primed reinstatement by 5-HT2CR agonists (Fletcher, et al., 2008; Neisewander & 
Acosta, 2007; Pentkowski, et al., 2010). We explored possible limitations to this finding 
in the discussion from Chapter 4 and suggest that increased anxiety from CP809101 in 
the BlA may have interfered with cue-primed reinstatement or that nonspecific effects of 
the drug at 5-HT2ARs may oppose the hypothesized action at 5-HT2CRs.   
A future direction for the Chapter 4 study is to examine the effects of a 5-HT2AR 
antagonist in the amygdala. 5-HT2ARs are found in the BlA, on both excitatory and 
inhibitory neurons (Bombardi, 2011; McDonald & Mascagni, 2007). It has been shown 
that 5-HT2AR agonism increases GABA inhibition from the BlA, but this effect is 
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attenuated after repeated stress (Jiang et al., 2009). 5-HT2ARs are also located in the CeA 
(Bombardi, 2011; Cornea-Hebert, et al., 1999; Wright, Seroogy, Lundgren, Davis, & 
Jennes, 1995), though the specific cellular localization has not yet been reported. Due to 
the opposing effects of 5-HT2AR antagonists and 5-HT2CR agonists on cocaine-related 
behaviors, it is possible that a 5-HT2AR antagonist in the BlA and CeA may have similar 
effects to a 5-HT2CR agonist in Chapter 4. 
An important issue to discuss when conducting pharmacological studies such as 
those in this dissertation is selectivy of the ligands being used. In Chapters 2 and 3, we 
used M100907 which is a highly selective 5-HT2AR antagonist. Due to the similarity of 
the 5-HT2A and 5-HT2CRs, the 5-HT2CR is the most likely receptor, aside from 5-HT2A, to 
be blocked by a non-selective 5-HT2AR antagonist. M100907 has greater than a 1000-fold 
selectivity for 5-HT2ARs over 5-HT2CRs (Kehne, et al., 1996), and reverses the effects of 
5-HT2AR agonists but not 5-HT2CR agonists (Dekeyne, et al., 1999; Gresch, et al., 2007; 
Hitchcock, et al., 1997; McCreary, et al., 2003; Vickers, et al., 2001; Wettstein, et al., 
1999). In Chapter 3, we used MK212, a moderately-selective 5-HT2CR agonist. While 
MK212 has affinity for the 5-HT2A, 5-HT2B, and 5-HT3Rs, it has a 150-fold selectivity 
for the 5-HT2CR relative to the other 5-HT2Rs (Cussac, et al., 2002; Glennon, et al., 1989; 
Porter, et al., 1999). Further, the effects of MK212 have been shown to be reversed with a 
5-HT2CR antagonist (Neisewander & Acosta, 2007; Pentkowski, et al., 2010; Stiedl, et 
al., 2007). In Chapter 4 we used a newer 5-HT2CR agonist, CP809101, which is more 
selective for the 5-HT2CR than MK212 and another older 5-HT2CR agonist, mCPP 
(Barnes & Sharp, 1999; Fletcher, et al., 2009). Additionally, we reversed the effects of 
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CP809101 with a 5-HT2CR antagonist, which greatly strengthens the argument that the 
effects of CP809101 were due to 5-HT2CR stimulation.  
In conclusion, this dissertation built upon the literature localizing the effects of 5-
HT2AR antagonists and 5-HT2CR agonists on cocaine-related behaviors and investigated a 
potential treatment mechanism via concurrent 5-HT2AR antagonism and 5-HT2CR 
agonism. There is a growing area of research on 5-HT2Rs and addiction, with the ultimate 
goal of identifying potential pharmacotherapeutic techniques to curb craving and 
motivation to seek addictive drugs. Studies such as those in this dissertation are essential 
in understanding the circuitry underlying the effects of 5-HT2R manipulations on 
cocaine-related behaviors, which, in turn, will aid in the use these mechanisms to treat 
addiction. Our findings, as well as others, offers strong support for the use of 5-HT2AR 
antagonists and 5-HT2CR agonists to attenuate the incentive motivational effects of 
cocaine and cocaine-associated cues, which contribute to relapse (Childress, et al., 1988; 
Jaffe, et al., 1989; Sinha, et al., 1999).  
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1 The number of animals shown for each test excludes those that did not reinstate or were outliers.  
Each animal received no more than 4 types of tests, and for each test type they received a vehicle 
infusion prior to one test and their assigned dose of M100907 prior to the other test, with order 
counterbalanced, resulting in a maximum of 8 microinfusions total.   
Table 1 Order of M100907 testing. 
 
Test 1 Test 2 Test 3 Test 4 
Self-Administration 
Testing (n=23)1 
Cue Reinstatement 
(n=42) 
Cocaine-Primed 
Reinstatement (n=39) 
M100907 Reinstatement 
(n=22) 
Cue Reinstatement 
(n=22) 
Cocaine-Primed 
Reinstatement (n=14) 
M100907 Reinstatement 
(n=14) 
Cue Reinstatement- 
Sucrose (n=10) 
M100907 Reinstatement 
(n=17)   
Locomotor Activity 
(n=24) 
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Table 2 Lever presses/h (mean ± SEM) during the first day of extinction and during the 
M100907 reinstatement tests.	  	  
Brain Region 
and Dose 
Assignments 
Active Lever 
Presses 
Inactive Lever Presses 
 
 
 
 
PFC 
First Day 
Extinction 
First Day 
Extinction 
Cue 
Reinstatement 
Cocaine 
Reinstatement 
M100907 
Reinstatement 
 
0.1 µg/side  
 
109.2 ± 16.5 
 
24.4 ± 6.9 
 
8.8 ± 4.1 
 
10.2 ± 5.1 
 
2.7 ± 0.8 
 
0.3 µg/side 
 
106.2 ± 11.5 
 
23.8 ± 4.7 
 
8.4 ± 1.9 
 
3.7 ± 1.5 
 
5.7 ± 1.6 
 
1.0 µg/side 
 
104.9 ± 18.3 
 
27.5 ± 10.0 
 
4.9 ± 1.0 
 
10.0 ± 7.1 
 
6.2 ± 2.6 
 
1.5 µg/side 
 
83.8 ± 12.9 
 
20.9 ± 4.0 
 
4.7 ± 1.0 
 
12.6 ± 8.1 
 
2.8 ± 1.4 
Cg2      
1.5 µg/side 70.8 ± 13.3 24.8 ± 6.3 12.7 ± 3.0   
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* 0.01 µg/side was co-infused with 0.1 µg/side SB242084 in the CeA in Experiment 3. 
Table 3 Lever presses/h (mean ± SEM) during the first day of extinction and during the 
CP809101 and SB242084 reinstatement tests. 
 
Brain region and 
CP809101 Dose  
 
Active Lever 
Presses 
Inactive Lever Presses 
  
 
BlA 
First Day 
Extinction 
First Day 
Extinction 
Cue 
Reinstatement 
Cocaine 
Reinstatement 
CP809101 
Reinstatement 
 
0.01 µg/side  
 
90.5 ± 17.0 
 
32.3 ± 14.2 
 
11.3 ± 4.4 
 
7.0 ± 3.0 
 
14.3 ± 7.0 
 
0.1 µg/side 
 
84.9 ± 13.0 
 
15.0 ± 5.3 
 
15.3 ± 3.7 
 
26.3 ± 12.0 
 
9.9 ± 2.9 
 
1.0 µg/side 
 
81.0 ± 12.5 
 
29.6 ± 14.5 
 
7.0 ± 1.3 
 
34.8 ± 26.0 
 
9.0 ± 2.2 
CeA      
0.01 µg/side 102.2 ± 11.6 29.2 ± 8.1 11.2 ± 5.3 15.7 ± 7.7 9.8 ± 3.6 
 
0.1 µg/side 
 
69.9 ± 13.0 
 
16.0 ± 5.8 
 
7.0 ± 1.6 
 
4.4 ± 1.3 
 
12.0 ± 2.0 
 
1.0 µg/side 
 
0.01 µg/side 
+SB242084* 
 
83.6 ± 18.3 
 
103.0 ± 13.5 
 
66.6 ± 31.3 
 
25.5 ± 5.3 
 
25.5 ± 11.1 
 
 
 
13.3 ± 3.8 
 
27.6 ± 15.4 
 
12.9 ± 5.2 
 
8.9 ± 1.4 
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Figure 1 Thionin-stained sections taken in the coronal plane demonstrating representative 
cannula placements in mPFC (A) and Cg2 (B). 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
A	   B	  
	   	   	  
126 
	  
Self-Administration
0.1 µg 0.3 µg 1.0 µg 1.5 µg
0
10
20
M100907
Vehicle
BaselineA.
N
um
be
r o
f R
ei
nf
or
ce
rs
/h
± 
SE
M
Baseline Vehicle M100907
0
10
20
*
B.
N
um
be
r R
ei
nf
or
ce
rs
/h
± 
SE
M
	  	  
Figure 2  Effects of M100907 on cocaine self-administration, expressed as the mean ± 
SEM number of reinforcers (infusions of cocaine with cues) received over a 1-h test 
session in each dosage group (A) and collapsed across dosage groups (B).  Animals 
assigned to receive 0.1 (n=6), 0.3 (n=6), 1.0 (n=6), or 1.5 (n=5) µg/0.2 µl/side M100907 
into the mPFC were tested on one day with their assigned dose (striped bar) and on 
another day with the vehicle (black bar), with order counterbalanced.  Baselines (white 
bar) were calculated as the average number of reinforcers obtained during the first h of 
the self-administration sessions immediately preceding each test.  There was a small, but 
significant decrease in responding on the M100907 test day relative to baseline when 
collapsed across dose (i.e., main effect of test day).  The asterisk (*) represents a 
significant difference from extinction baseline, test of simple main effects, p<0.05.    
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Figure 3  Effects of M100907 pretreatment on cue-elicited reinstatement of cocaine-
seeking behavior when injected directly into the mPFC, expressed as mean responses/h ± 
SEM on the active lever.  Animals assigned to receive 0.1 (n=13), 0.3 (n=12), 1.0 (n=14), 
or 1.5 (n=17) µg/0.2 µl/side M100907 into the mPFC were tested on one day with their 
assigned dose (striped bar) and on another day with the vehicle (black bar), with order 
counterbalanced.  These pretreatments were infused within 1 min before placing the 
animals into the self-administration chambers, where light and tone cues were available 
response-contingently on an FR1 schedule.  Baselines (white bar) were calculated as the 
average number active lever presses during the extinction sessions immediately preceding 
each test.  The asterisk (*) represents a significant difference from extinction baseline, 
test of simple main effects, p<0.05.  The plus sign (+) represents a significant difference 
from vehicle pretreatment session, planned t-tests, p<0.05.	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Figure 4  The effects of 1.5 µg/0.2 µl/side M100907 on cue-elicited reinstatement of 
cocaine-seeking behavior when injected directly into the Cg2 region of the anterior 
cingulate cortex (n=8), which served as an anatomical control site.  Animals received 1.5 
µg/0.2 µl/side M100907 and were tested on one day with their assigned dose (striped bar) 
and on another day with the vehicle (black bar), with order counterbalanced.  These 
pretreatments were infused within 1 min before placing the animals into the self-
administration chambers, where light and tone cues were available response-contingently 
on an FR1 schedule.  Baselines (white bar) were calculated as the average number active 
lever presses during the extinction sessions immediately preceding each test.  The 
asterisk (*) represents a significant difference from extinction baseline, test of simple 
main effects, p<0.05.   
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Figure 5  Effects of M100907 pretreatment on cocaine-primed reinstatement of cocaine-
seeking behavior, expressed as mean responses/h ± SEM on the active lever in each 
dosage group (A) and collapsed across dosage groups (B).  Animals assigned to receive 
0.1 (n=13), 0.3 (n=13), 1.0 (n=13), or 1.5 (n=14) µg/0.2 µl/side M100907 into the mPFC 
were tested on one day with their assigned dose (striped bar) and on another day with the 
vehicle (black bar), with order counterbalanced.  These pretreatments were infused, and 
immediately after the animals received the cocaine prime (10 mg/kg, i.p.), and were then 
immediately placed into the self-administration chambers.  No cues were presented 
during the test sessions.  Baselines (white bar) were calculated as the average number of 
active lever presses during the extinction sessions immediately preceding each test.  
When collapsed across doses (B) there was a significant increase in responding on both 
the vehicle and M100907 test days relative to extinction baseline and a significant 
decrease in responding on the M100907 test day relative to the vehicle test day.  The 
asterisk (*) represents a significant difference from extinction baseline, test of simple 
main effects, p<0.05. The plus sign (+) represents a significant difference from vehicle 
test day, test of simple main effects, p<0.05. 
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Figure 6  Effects of M100907 priming injections on reinstatement of cocaine-seeking 
behavior, expressed as mean responses/h ± SEM on the active lever.  Animals received 
0.1 (n=13), 0.3 (n=13), 1.0 (n=14), or 1.5 (n=13) µg/0.2 µl/side M100907 infused into the 
mPFC on one test day (striped bar) and vehicle on another day (black bar), with order 
counterbalanced. They were placed into the self-administration chambers immediately 
after these pretreatments.  Baselines (white bar) were calculated as the average number of 
active lever presses obtained during the extinction sessions immediately preceding each 
test.  No cues were presented during the test sessions. 	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Figure 7  Effects of M100907 pretreatment on cue reinstatement of sucrose-seeking 
behavior (n=10), expressed as mean responses/h ± SEM on the active lever.  Animals 
were tested on one day with 1.5 µg/side M100907 (striped bar) and on another day with 
the vehicle (black bar), with order counterbalanced.  These pretreatments were infused 
within 1 min before placing the animals into the self-administration chambers, where 
light and tone cues were available response-contingently on an FR1 schedule.  Baselines 
(white bar) were calculated as the average number of active lever presses obtained during 
the extinction sessions immediately preceding each test.  There was a significant increase 
in responding on both the vehicle and M100907 test days relative to extinction baseline.  
The asterisk (*) represents a significant difference from extinction baseline, test of simple 
main effects, p<0.05. 	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Figure 8  Effects of M100907 pretreatment on locomotor activity, expressed as total 
movement (m) during a 90-min test session.  Animals received either vehicle or 1.0 
µg/side M100907 into the mPFC (n=12/group) and were given an injection 5 min later of 
cocaine (10 mg/kg, i.p.) for one test and saline (10 mg/kg, i.p.) for the other test, with 
order counterbalanced.  They were then immediately placed into the test chambers.  A 
pound sign (#) indicates a difference from saline test day, ANOVA main effect, P<0.05. 
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Figure 9 Representative images of Fos positive nuclei in the dorsolateral CPu for animals 
that received either cocaine (a), saline (b), or cocaine + M100907 and MK 212 cocktail 
(c) and schematic representation of coronal sections of the rat brain taken at +3.2 (d) and 
+1.6 mm from Bregma (e; Paxinos and Watson, 1998). Numbers in the sections represent 
the regions analyzed for Fos as follows: (1) prelimbic cortex (PrL); (2) infralimbic cortex 
(IL); (3) dorsolateral CPu; (4) NAcC; (5) NAcSh. Scale bar on the first image (a) is equal 
to 100 µm. 
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Figure 10 Effects of 0.025 (a), 0.05 (b), and 0.1 (c) mg/kg M100907 (n=8/dose group) on 
cocaine hyperlocomotion, expressed as the mean ± SEM total distance traveled in meters 
across 15-min time bins relative to the last 15-min of habituation (baseline; BL), or for 
the entire 1-h session (insert). Dose was a between-subjects factor, while test day (vehicle 
or M100907) was a within-subjects factor. In between habituation and cocaine 
hyperlocomotion testing, rats were injected subcutaneously with vehicle on one test day 
(left) and their assigned dose of M100907 on the other test day (right), with order 
counterbalanced; 5 min later they were injected with cocaine (15 mg/kg, i.p.), indicated 
by the dotted vertical lines. Only the 0.025 mg/kg dose failed to have any effect on 
cocaine hyperlocomotion. The asterisk (*) represents a significant difference from 
baseline, P<0.05. The plus sign (+) represents a significant difference from the vehicle 
test day, P<0.05. 
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Figure 11 Effects of 0.125 (a), 0.25 (b), and 0.5 (c) mg/kg MK212 (n=8/ dose group) on 
cocaine hyperlocomotion, expressed as the mean ± SEM total distance traveled in meters 
across 15-min time bins relative to the last 15-min of habituation (baseline; BL). Dose 
was a between-subjects factor, while test day (vehicle or M100907) was a within-subjects 
factor. In between habituation and cocaine hyperlocomotion testing, animals were 
injected subcutaneously with vehicle on one test day (left) and their assigned dose of 
MK212 on the other test day (right), with order counterbalanced; 5 min later they were 
injected with cocaine (15 mg/kg, i.p.), indicated by the dotted vertical lines. Only the 
0.125 mg/kg dose failed to have any effect on cocaine hyperlocomotion. The asterisk (*) 
represents a significant difference from baseline, P<0.05. The plus sign (+) represents a 
significant difference from respective time point on the vehicle test day, P<0.05. 
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Figure 12 Panel a shows the effects of cocaine, saline, 0.025 mg/kg M100907 + cocaine, 
0.125 mg/kg MK212 + cocaine, and M100907 + MK212 cocktail + cocaine (n=8/group) 
on cocaine hyperlocomotion, expressed as the mean ± SEM total distance traveled in 
meters across 15-min time bins relative to the last 15-min of habituation (baseline; BL). 
Panel b shows the cumulative data for the entire 60-min session. In between habituation 
and cocaine hyperlocomotion testing, animals were injected subcutaneously with vehicle 
on one test day (left) and their assigned dose of MK212 on the other test day (right), with 
order counterbalanced; 5 min later they were injected with cocaine (15 mg/kg, i.p.), 
indicated by the dotted vertical lines. In both graphs, only the saline and the M100907 + 
MK212 cocktail + cocaine groups showed a significant difference from the cocaine alone 
group, indicating that M100907 and MK212 only had an effect when given in 
combination. The asterisk (*) represents a significant difference from the cocaine group, 
P<0.05.  
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Figure 13 Effects of saline, 0.025 mg/kg M100907, 0.125 mg/kg MK212, and 
M100907/MK212 cocktail (n=8/group) on spontaneous locomotion, expressed as the 
mean ± SEM total distance traveled in meters across 15-min time bins (a) and as total 
locomotion for the 1-h test (b). Animals were injected subcutaneously with their assigned 
drug, and 5-min later were given a 1-hr test for locomotor activity. There were no 
differences in locomotion between groups. 
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Figure 14 Effects of saline, 15 mg/kg cocaine, 0.025 mg/kg M100907 + cocaine, 0.125 
mg/kg MK212 + cocaine, and M100907 + MK212 cocktail + cocaine (n=8/group) on Fos 
activation in the dorsolateral CPu (a), NAc core (b) and shell (c), and infralimbic (d) and 
prelimbic (e) PFC, expressed as the mean ± SEM of percent of control (saline alone 
group). The dotted line indicates reference point for change from saline control (i.e., 
100%,). All animals underwent locomotor activity testing and were sacrificed 90 min 
after drug injections. Animals were perfused and brains were harvested for Fos 
immunohistochemistry. There was a significant difference between saline and cocaine 
groups, indicating that cocaine increased Fos expression in the CPu. There was also a 
difference between the M100 + cocaine and MK212 + cocaine groups, which shows that 
these drugs alone had no effect on cocaine-induced Fos activation. There was no 
difference between the saline and cocktail + cocaine groups, indicating that the cocktail 
decreased Fos activation levels back to baseline. There were no differences between any 
of the groups in any regions of the NAc or PFC. The asterisk (*) represents a significant 
difference from the saline group, P<0.05.  
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Figure 15 Histological reconstructions (left) with shaded regions showing where 
cannulae tips were considered correctly placed for the BlA (A) and CeA (B). The right 
sides show pictographs of cresyl violet stained tissue samples with methylene blue 
microinfusions for the BlA (A) and CeA (B). 
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Figure 16 Effects of CP809101 priming injections in the BlA on reinstatement 
responding, expressed as the mean ± SEM number of active lever presses received over a 
1-h test session in each dosage group. Animals assigned to receive 0.01 (n=7), 0.1 (n=8) 
or 1.0 (n=8) µg/0.2µL/side CP809101 into the BlA were tested on one day with their 
assigned dose (striped bar) and on another day with the vehicle (BlAck bar), with order 
counterbalanced. Baselines (white bars) were calculated as the average number of active 
lever presses during the extinction sessions immediately preceding each test. There was 
no effect of vehicle or CP809101 pretreatment on reinstatement responding. 
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Figure 17 Effects of CP809101 in the BlA on cue-primed reinstatement, expressed as the 
mean ± SEM number of active lever presses received over a 1-h test session in each 
dosage group. Animals assigned to receive 0.01 (n=6), 0.1 (n=8) or 1.0 (n=8) 
µg/0.2µL/side CP809101 into the BlA were tested on one day with their assigned dose 
(striped bar) and on another day with the vehicle (BlAck bar), with order 
counterbalanced. These pretreatments were infused within 1 min before placing the 
animals into the self-administration chambers, where light and tone cues were available 
response-contingently on an FR 1 schedule. Baselines (white bars) were calculated as the 
average number of active lever presses during the extinction sessions immediately 
preceding each test. The asterisk (*) represents a significant difference from extinction 
baseline, test of simple main effects, P<0.05. All groups showed significant 
reinstatement, but CP809101 had no effect on cue-primed reinstatement relative to 
vehicle. 
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Figure 18 Effects of CP809101 in the BlA on cocaine-primed reinstatement, expressed as 
the mean ± SEM number of active lever presses received over a 1-h test session in each 
dosage group. Animals assigned to receive 0.01 (n=5), 0.1 (n=7) or 1.0 (n=8) 
µg/0.2µL/side CP809101 into the BlA were tested on one day with their assigned dose 
(striped bar) and on another day with the vehicle (BlAck bar), with order 
counterbalanced. These pretreatments were infused immediately before the animals 
received the cocaine prime (10 mg/kg, i.p.) and were then immediately placed into the 
self-administration chambers. No cues were presented during the test sessions. Baselines 
(white bars) were calculated as the average number of active lever presses during the 
extinction sessions immediately preceding each test. The asterisk (*) represents a 
significant difference from extinction baseline, test of simple main effects, P<0.05. All 
groups showed significant reinstatement, but CP809101 had no effect on cue-primed 
reinstatement relative to vehicle. 
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Figure 19 Effects of CP809101 in the BlA on the percent of time spent on the open arms 
of the EPM. Animals assigned to receive vehicle (n=3), 0.01 (n=7), 0.1 (n=4) or 1.0 (n=8) 
µg/0.2µL/side CP809101 into the BlA were given one 10-min test on the EPM. These 
pretreatments were infused 5-min before animals were placed on the center of the EPM. 
The plus sign (+) indicates a significant difference from the vehicle group, planned 
comparison, (P<0.05). 
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Figure 20 Effects of CP809101 in the BlA on an anxiety-index score, which accounts for 
percent of time spent in open arms as well as open arm entries on the EPM. Animals 
assigned to receive vehicle (n=3), 0.01 (n=7), 0.1 (n=4) or 1.0 (n=8) µg/0.2µL/side 
CP809101 into the BlA were given one 10-min test on the EPM. These pretreatments 
were infused 5-min before animals were placed on the center of the EPM. The plus sign 
(+) indicates a marginally significant difference from the vehicle group, planned 
comparison, (P=0.052). 
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Figure 21 Effects of CP809101 in the BlA on spontaneous locomotor activity. Animals 
assigned to receive vehicle (n=3), 0.01 (n=7), 0.1 (n=4) or 1.0 (n=8) µg/0.2µL/side 
CP809101 into the BlA were given one 10-min test on the EPM. These pretreatments 
were infused 5-min before animals were placed on the center of the EPM. There were no 
effects of CP809101 on locomotor activity. 
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Figure 22 Effects of CP809101 priming injections in the CeA on reinstatement 
responding, expressed as the mean ± SEM number of active lever presses received over a 
1-h test session in each dosage group. Animals assigned to receive 0.01 (n=6), 0.1 (n=9) 
or 1.0 (n=8) µg/0.2µL/side CP809101 into the CeA were tested on one day with their 
assigned dose (striped bar) and on another day with the vehicle (BlAck bar), with order 
counterbalanced. Baselines (white bars) were calculated as the average number of active 
lever presses during the extinction sessions immediately preceding each test. There was 
no effect of vehicle or CP809101 pretreatment on reinstatement responding. 
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Figure 23 Effects of CP809101 in the CeA on cue-primed reinstatement, expressed as the 
mean ± SEM number of active lever presses received over a 1-h test session in each 
dosage group. Animals assigned to receive 0.01 (n=6), 0.1 (n=9) or 1.0 (n=8) 
µg/0.2µL/side CP809101 into the CeA were tested on one day with their assigned dose 
(striped bar) and on another day with the vehicle (BlAck bar), with order 
counterbalanced. These pretreatments were infused within 1 min before placing the 
animals into the self-administration chambers, where light and tone cues were available 
response-contingently on an FR 1 schedule. Baselines (white bars) were calculated as the 
average number of active lever presses during the extinction sessions immediately 
preceding each test. The asterisk (*) represents a significant difference from extinction 
baseline, test of simple main effects, P<0.05. All groups showed significant 
reinstatement, but CP809101 had no effect on cue-primed reinstatement relative to 
vehicle. 
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Figure 24 Effects of CP809101 in the CeA on cocaine-primed reinstatement, expressed 
as the mean ± SEM number of active lever presses received over a 1-h test session in 
each dosage group. Animals assigned to receive 0.01 (n=6), 0.1 (n=7) or 1.0 (n=7) 
µg/0.2µL/side CP809101 into the BlA were tested on one day with their assigned dose 
(striped bar) and on another day with the vehicle (BlAck bar), with order 
counterbalanced. These pretreatments were infused immediately before the animals 
received the cocaine prime (10 mg/kg, i.p.) and were then immediately placed into the 
self-administration chambers. No cues were presented during the test sessions. Baselines 
(white bars) were calculated as the average number of active lever presses during the 
extinction sessions immediately preceding each test. The asterisk (*) represents a 
significant difference from extinction baseline, test of simple main effects, P<0.05. The 
plus sign (+) represents a significant difference from vehicle test day, P<0.05. All groups 
showed significant reinstatement except for the 0.01 µg dose group, which was also 
significant different from the corresponding vehicle test day. 
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Figure 25 Effects of CP809101 in the CeA on amount of time spent in the open arms of 
the EPM. Animals assigned to receive vehicle (n=10), 0.01 (n=8), 0.1 (n=7) or 1.0 (n=6) 
µg/0.2µL/side CP809101 into the CeA were given one 10-min test on the EPM. These 
pretreatments were infused 5-min before animals were placed on the center of the EPM. 
There was no effect of CP809101 in the CeA on amount of time spent in the open arms of 
the EPM. 
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Figure 26 Effects of CP809101 in the CeA on an anxiety-index score, which accounts for 
percent of time spent in open arms as well as open arm entries on the EPM. Animals 
assigned to receive vehicle (n=10), 0.01 (n=8), 0.1 (n=7) or 1.0 (n=6) µg/0.2µL/side 
CP809101 into the CeA were given one 10-min test on the EPM. These pretreatments 
were infused 5-min before animals were placed on the center of the EPM. There was no 
effect of CP809101 in the CeA on anxiety-index score. 
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Figure 27 Effects of CP809101 in the CeA on spontaneous locomotor activity. Animals 
assigned to receive vehicle (n=10), 0.01 (n=8), 0.1 (n=7) or 1.0 (n=6) µg/0.2µL/side 
CP809101 into the CeA were given one 10-min test on the EPM. These pretreatments 
were infused 5-min before animals were placed on the center of the EPM. There were no 
effects of CP809101 on locomotor activity. 
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Figure 28 Effects of CP809101 priming injections in the CeA on reinstatement 
responding, expressed as the mean ± SEM number of active lever presses emitted over a 
1-h test session in each dosage group. Animals assigned to receive either 0.01 
µg/0.2µL/side CP809101 (n=9) or 0.1 µg/0.2µL/side SB242084 (n=7) into the CeA were 
tested on one day with their assigned dose (striped bar) and on another day with the 
vehicle (BlAck bar), with order counterbalanced. Baselines (white bars) were calculated 
as the average number of active lever presses during the extinction sessions immediately 
preceding each test. There was no effect of vehicle, CP809101, or SB242084 
pretreatment on reinstatement responding. 
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Figure 29 Effects of CP809101 and SB242082 in the CeA on cocaine-primed 
reinstatement, expressed as the mean ± SEM number of active lever presses received 
over a 1-h test session in each dosage group. Animals assigned to receive either 0.01 
µg/0.2µL/side CP809101 (n=7) or 0.01 µg/0.2µL/side CP809101 + 0.1 µg/0.2µL/side 
SB242084 (n=5) into the CeA were tested on one day with their assigned dose (striped 
bar) and on another day with the vehicle (BlAck bar), with order counterbalanced. These 
pretreatments were infused immediately before the animals received the cocaine prime 
(10 mg/kg, i.p.) and were then immediately placed into the self-administration chambers. 
No cues were presented during the test sessions. Baselines (white bars) were calculated as 
the average number of active lever presses during the extinction sessions immediately 
preceding each test. The asterisk (*) represents a significant difference from extinction 
baseline, test of simple main effects, P<0.05. The plus sign (+) represents a significant 
difference from vehicle test day, P<0.05. All groups showed significant reinstatement, 
however the 0.01 µg CP809101 group showed significantly lower responding on 
CP809101 test day relative to vehicle. 
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